Program

 

 

2 October 2019

 8:30 AMWelcome Coffee
 9:00 AM

Welcome and Opening
Jonathan Schapiro, MD
Sheba Medical Center, Israel

 Managing Today’s Complex HIV Patient Satellite Symposium
Chairs: Charles Boucher and Jonathan Schapiro
 9:05 AMHow to Identify the Complex HIV Patient and Approach to Treatment
Michael Kozal, MD
Yale University, United States
 9:30 AM

Kuritzkes, Daniel 2016 120Drug Options for the Complex HIV Patient: What Are They and How Best to Use Them?
Dan Kuritzkes, MD
Harvard Medical School, United States

 Clinical Case Discussions
 9:55 AMClinical Case #1: Focus on Drug Resistance
Michael Kozal, MD
Yale University, United States
 10:15 AMClinical Case #2: Focus on Comorbidities and Toxicity
David Hardy, MD, AAHIVS
Johns Hopkins University School of Medicine, United States
  10:35 AMDiscussion
 10:50 AMSummary and Take Home Messages
Jonathan Schapiro, MD
 11:00 AMEnd of Symposium

 

Program

This online program will consist of six modules: three introductory webcast presentations about failure and treatment switching, and three clinical case studies.

INTRODUCTORY MODULES

Module 1: Virological Failure
Definitions, challenges, and solutions around identifying failure
Nicholas Paton, MD, FRCP

Module 2: Switching to Second-Line
Current guidelines, recent study results, options and recommendations
Mark Boyd, MD, FRACP

Module 3: Future of Second-Line Therapy
New data, future challenges and ways forward
Mark Boyd, MD, FRACP

CLINICAL CASE PRESENTATIONS

We will discuss cases of patients who failed treatment and how to switch to second-line treatment. Join the course and learn about common causes of treatment failure and the challenges around switching patients to second line treatment in different regions and settings.

Francois Venter, MD, FCP
Jonathan Schapiro, MD
Nicholas Paton, MD, FRCP

PRE- AND POST-ASSESSMENTS

Prior to participating in this course, participants will need to answer a pre-assessment quiz to assess baseline knowledge. Upon completion of the course, a post-assessment will be given to determine knowledge gained. Once the post-assessment and a final course evaluation have been submitted, participants may request a certificate of participation. 

 

 

 

Program

 Preliminary program
 

Day 1 - Friday, 6 March 2020

 
 08:30 AMOpening of the workshop 
 Session 1: Research in HIV and women over the last decade: successes and challenges 
 08:45 AMAntiretroviral therapy, women in clinical trials  
 09:00 AMPrevention of mother to child transmission 
 09:15 AMPrevention of HIV transmission in women 
 09:30 AMComorbidities of importance to women 
 09:45 AMPsychosocial issues for HIV infected women 
 10:00 AMInvolvement of women living with HIV in research 
    
 10:15 AMCoffee Break 
    
  Abstract-driven presentations 
 10:45 

4 Slots

 
 11:45 AMDiscussion 
 12:15 PMGroup Picture 
    
 12:30 PMLunch
 
    
 Session 2: Debate: Does U=U apply to women?
 
 01:30 PM Does U=U apply to women? A pro-con debate involving experts and community representatives 
    
 02:30 PM

Coffee Break

 
  Abstract-driven presentations 
 03:00 PM

4 Slots

 
 04:00 PMDiscussion 
    
 04:15 PMWelcome drinks, poster viewing session and guided poster tour 1 
    
 

Day 2 - Saturday, 7 March 2019

 
 Session 3: 90:90:90- which women are being left behind?
 
 08:30 AMNorth America 
 
 08:45 AMEastern Europe 
 09:00 AMAfrica 
 09:15 AMSouth America 
 09:30 AMSoutheast Asia/Australia 
 09:45 AMDiscussion 
    
 10:15 AMCoffee Break, poster viewing session and guided poster tour 2
 
    
 Session 4: Abstract - driven presentations
 
 11:15 AM 4 Slots 
 12:15 PMDiscussion 
    
 12:30 PMLunch 
    
 Session 5: Women surviving and aging with HIV
 
 01:30 PMPoppy cohort 
 01:45 PMAGEHIV cohort 
 02:00 PMCommunity perspective 
  Abstract-driven presentation 
 02:15 PM 3 Slots 
 03:00 PMDiscussion 
    
 03:15 PMClosing of the workshop 

 

Program

Click here to view the program of COLDA 2019: COLDA PROGRAM

COLDA 2019 featured an exceptional program with invited lecturers, round table discussions, and interactive participation from delegates.

Parallel Pre-meeting Training Workshops
Two parallel pre-meeting training workshops took place. 

1.
This parallel session consisted of two separate presentations. 

Basic upper endoscopy

• Identification of the scope
• Introduction if the scope

Basic colonoscopy
• Identification of the scope
• Introduction of the scope
• Identification of Cecum
• Loop management

2. Point of care testing

This workshop was hosted by FIND - Foundation for Innovative New Diagnostics.
Insufficient coverage of viral hepatitis testing services is a major barrier to increase access to care and eventually eliminate hepatitis B (HBV) and hepatitis C (HCV) virus. HBV and HCV testing services can be substantially improved by expanding the use of existing and introducing new diagnostic tools.

This two-hour session covered key concepts on both HBV and HCV and included a ‘wet’ training in which demonstrations were provided on some of the available diagnostic technologies.

For more information, please click here.

 

 The 2019 program consisted of the following sessions:

  • Capacity-building sessions
  • State-of-the-art lectures
  • Panel discussion sessions
  • Abstract presentations
  • Clinical case discussions

Program

The 6th edition of the International HBV Cure Workshop featured the world's most prominent and distinguished speakers that discussed the most current and trending issues in the field. 

 

 Wednesday, 6 November 2019

 8:00

Welcome
Harry Janssen
Toronto Centre for Liver Disease, Canada

 Session 1: Review of Nucleoside analogue Stopping studies
Chairs: Marion Peters & David Wong
 8:10

Stopping Nucleos(t)ide Analogues: Clinical outcomes of HBs Loss, retreatment and flares
Pietro Lampertico
University of Milan

 8:25

Virological biomarkers in patients stopping Nucs
Florian van Bommel
University Hospital Leipzig

 8:40

Immunological response after stopping Nucs
Andre Boonstra
Erasmus Medical Center, the Netherlands

 8:55Discussion
   
 Session 2: New Endpoints and Biomarkers
Chairs: Robert Gish & Scott Fung
 9:20 AM

Review of the FDA/EMA HBV Endpoints Meeting
Fabien Zoulim
INSERM, France

 9:35 AM

Are HBcrAg, HBV RNA and anti-HBc Viable Biomarkers
Florian van Bommel
University Hospital Leipzig

 9:50 AM

Are ALT Flares Associated with Improved Virological Clearance
Harry Janssen
Toronto Centre for Liver Disease

 10:05 AMDiscussion
   
 10:25 AMCOFFEE BREAK
   
 Session 3: How to make immunology curative
Chairs: Adam gehring & Georg Lauer
 10:40 PM

High Resolution of Exhausted T cells Ex Vivo in Chronic HBV Infection
Robert Thimme
University of Freiburg, Germany

 10:55 PM

Restoration of B cell Antibody Production in Chronic HBV patients
Mala Maini
University College London

 11:10 PM

Using FNAB to Investigate Intrahepatic Immunology
Adam Gehring
Toronto Centre for Liver Disease, Canada

 11:25 AM

Springbank RIG-I Agonist (Inarigivir)
Cheleas MacFarlane
Springbank Pharmaceuticals, Inc. 

 11:35 AMGilead TLR8 agonist (GS-9688)
Simon Fletcher
Gilead Sciences
 11:45 AM

Roche TLR-7 agonist
Lu Gao
Roche, China

 11:55 AMDiscussion
   
 12:30 PMLunch
   
 Session 4: Update on Viral Targets for HBV/HDV Therapy 
Chairs: Stephen Locarnini & Raymond Schinazi
 1:30 PM

Mechanisms of cccDNA Maintenance and progress on Measurement
Massimo Levrero
Cancer Research Center of Lyon - Inserm U1052

 1:45 PM

Capsid inhibitor/cccDNA Inhibitor - Roche
Lu Gao
Roche, China

 1:55 PM

Elimination of Residual HBV Replication and Prevention of cccDNA Generation with the Combination of NrtI and Core Inhibitor
Richard Colonno
Assemby Biosciences

 2:05 PMsIRNA based therapy for Chronic Hepatitis B Treatment
Michael Biermer
Janssen
 2:15 PM

NAP's latest update in HBV and HDV
Andrew Vaillant
Replicor

 2:25 PM

MyrB + IFN effect on HBV & HDV
Stefan Urban
Heidelberg University Hospital

 2:35 PM

HDV Trials
Robert Gish
Robert G. Gish Consultants LLC

 2:45 PM Discussion
   
 3:30 PMCoffee Break
 Session 5: New Drug Combinations and Study Design
Chairs: Harry Janssen & Fabien Zoulim
 3:45 PMFDA Guidance on New Combinations
Poonam Mishra
US Food and Drug Administration, United States
 4:00 PM

Hypothesized Synergies in new cobmination treatment beyond nucs
Jordan Feld
Toronto Center for Liver Disease

 4:15 PM

Study Design with New Combinations
Marion Peters
University of California, San Francisco

 4:30 PMDiscussion
 5:15 PMClosure of workshop
Harry Janssen
   
 6:30 PMNetworking Dinner

 

Program

The program will consist of keynote talks, state-of-the-art lectures, oral abstract presentations and poster viewing sessions. Please click here to view the full agenda.

The list of abstract presenters can be viewed here.

Program

The workshop will be abstract-driven and will be guided by cross-cutting themes in the field of  adolescent health and HIV care. Each session will include an invited plenary session on a key issue in the field, followed by abstract presentations, debates and discussions.  The following themes will be addressed: 

- Structural and systematic barriers
- Youth leadership, engagement and advocacy 
- Intervention and Service Delivery approaches 
- Biomedical interventions and clinical management 
- Communications and behavior change: interpersonal to mass media
- Mental health and psychosocial support 
- Scaling up interventions: improving the quality and sustainability of programs

Program

 

 

Saturday, 20 July

 
 8:00 AMRegistration and coffee 
 8:30 AMWelcome 
 8:35 AMIntroductions and goals 
    
 Session 1: What are we talking about - context and epidemiology
 
 8:45 AMGomez Regalado, Amaranta - 2019Terminology, definitions, life course perspective regarding sexual orientation, gender identity and gender expression (SOGIE)
Amaranta Gómez Regalado; Universidad Veracruzana, Xalapa, México
 
 9:10 AM

Global overview on HIV and STI epidemiology among transgender people prevalence / incidence
Ayden Scheim, PhD; University of California, San Diego, CA, USA

 
 9:35 AM

Panel Discussion on transgender health, social and epidemiologic situations in different settings
Moderator: JoAnne Keatley, MSW, Center of Excellence for Transgender Health UCSF, USA
Panel members:
- Max Appenroth, Charité Universitätsmedizin Berlin, Germany
- Leigh Ann van der Merwe, SHE, South Africa
- Jessica Xavier, USA
- Alexandra Rodriguez, IRGT, Mexico
- Kritima Samitpol (Jemma), Thai Red Cross AIDS Research Centre, Thailand

 
 10:30 AMCOFFEE BREAK 
    
 Session 2: Gender-affirming  care
 
 11:00 AM Cindy Chew 5/1/18Mental health and behavioral health: depression, substance use, and internalized stigma
Jae Sevelius, PhD; UCSF Centre of Excellence for Transgender Health, San Francisco, CA, USA
 
 11:25 AM

Deutsch, Madeline - 2019 120x160

Hormone use and hormone monitoring
Madeline Deutsch, MD, MPH; UCSF Medical Center, San Francisco, CA, USA

 
 11:50 AM

Radix, Asa 2019 120x160

Hormones, ARVs and PrEP
Asa Radix, MD, MPH; Callen-Lorde Community Health Centre, New York, NY, USA

 
 12:15 PM

Suwajo, Poonpissamai 2019 120x160

Sex Reassignment Surgery and Post-op Care
Poonpissamai Suwajo, MD; Chulalongkorn University, Bangkok, Thailand

 
 12:40 PM

Poteat, Tonia 2019 120x160

Addressing social determinants in the context of HIV care
Tonia Poteat, PhD, PA-C, MPH; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

 
  
 1:05 PMLUNCH 
    
 Session 3: HIV prevention and treatment service delivery models
 
 2:00 PM

Araña, Yanyan 2019 120x160

Community-led service delivery model
Yanyan Araña; Victoria by Loveyourself, Manila, the Philippines

 
 2:25 PM

Acevedo, Maribel - 2019 120 x 160

Primary care clinic-based delivery model
Maribel Acevedo, MD; Centro Ararat, San Juan, Puerto Rico

 
 2:50 PM

Sexual health clinic-based delivery model
Rena Janamnuaysook, MBA; Tangerine Clinic, Bangkok, Thailand

 
 3:15 PM

Iliassou Mfochive Njindam, MD, MPH

Hospital-based delivery model
Iliassou  Mfochive Njindam, MD, MPH; CHAMP, Cameroon

 
 3:40 PMDiscussion 
 4:00 PMCOFFEE BREAK 
    
 Session 4: Identifying strategies for providing effective transgender health 
 
 4:30 PMGoldstein, Zil 2019 120x160Comprehensive primary health care service for transgender people: who, what and how
Zil Goldstein, BSN, RN, MSN, FNP-BC, AAHIVS; Callen-Lorde Community Health Centre, New York, NY, USA
 
 4:55 PMPanel discussion:  How to move forward 
 5:30 PMNext steps 
 5:45 PMClosing remarks 
 6:00 PMReception 
 7:30 PMWorkshop dinner (pre-registration required, click here for more information) 

 

Support

Financial backing from the corporate community will help us deliver an impactful and essential meeting experience. This collaboration plays a vital for both the organizational as well as the scientific success of the program.

Your financial support will help advance the field significantly by providing healthcare professionals with a platform to present findings, discuss conclusions, and create strategies for the future.

Show your commitment to the cause and get in touch with us for a tailored support package, please contact Ms. Goda Adomonis at goda.adomonis@vironet.com or call +31 30 2307147.

Corporate Support

Platinum Level

Platinum Level

Platinum level

Contributor

Contributor level

Program

 

1:00 PMWalk-in lunch
2:00 PMOpening
2:10 PMThe 90-90-90 goals and Fast Track Cities - A success story?
Mark Nelson - Chelsea and Westminster Hospital, UK
2:40 PMChoo, Martin 2019 120x160Home is where the heart is: Institutional Stigma in Asia
Martin Choo - Asia Pacific Council of AIDS Service Organizations, Malaysia
3:00 PMStigma discrimination – Transgender’s perspective
Rena Janamnuaysook - Thai Red Cross AIDS Research Centre, Thailand
3:20 PMStigma discrimination - the Asia Pacific/Southeast Asia story
Bruce Agins - University of California San Francisco, USA

3:40 PM

Coffee break

4:10 PMStigma discrimination - Health Care perspective - how deep is the problem really (on the ground experience) 
Huu Thuy Do - Vietnam Authority of AIDS Control (VAAC), Ministry of Health, Vietnam
4:30 PMPanel discussion: How to move forward
Moderator: Nittaya Phanuphak  - Thai Red Cross AIDS Research Centre, Thailand
5:00 PMClosure of the Symposium
5:30 PMNetworking dinner

 

Program

Tuesday 14 MayWednesday 15 MayThursday 16 May
 

Tuesday 14 May

 Opening of the Workshop
 4:00 PM

Opening Remarks
David Burger, PharmD, PhD - Radboud University Medical Centre, the Netherlands

 
  Session 1 - 20 Years in Review
Chairs: David Burger & David Back
 
 4:15 PM

Drug-drug interactions: all you need to know beyond www.hiv-druginteractions.org
Marta Boffito, MD, PhD - Chelsea and Westminster Hospital, United Kingdom

 
 4:45 PM

Courtney Fletcher, PharmD

Stop measuring ARV levels in plasma!
Courtney Fletcher, PharmD - University of Nebraska, United States

 
 5:15 PM

Terrence Blaschke, MD

50% adherence is enough with modern ARVs, right?
Terrence Blaschke, MD - Stanford University, United States

 
 5:45 PM

Jonathan Schapiro, MD

Modern ARVs do not develop resistance, do they?
Jonathan Schapiro, MD - Sheba Medical Center, Israel

 
 6:15PMRound-Table Discussion 
   
 Welcome Reception + Group Photo 
   
 

Wednesday 15 May

 Session 2 - Novel strategies for prevention and therapy
Chairs: Andrea Calcagno & Kimberly Scarsi
 8:30 AM

The ‘third wave’ of TB drug development: what’s on the horizon (for patients with or without HIV)
Kelly Dooley, MD, PhD - Johns Hopkins University, United States

 
 Abstract-driven Presentations
 9:00 AM

Efavirenz pharmacokinetics in HIV/TB coinfected persons initiating ART while receiving high dose rifapentine
Anthony Podany, PharmD - University of Nebraska Medical Center, United States

 #1
 9:15 AMIn silico design of a microarray patch as a multipurpose prevention technology
Rajith Rajoli - Univerisity Of Liverpool, United Kingdom

 #2
 9:30 AMPopulation pharmacokinetics of VRC01 in infants and adults
Jerry Li - University of California San Diego, United States
 #3
9:45 AMThe initial Phase 1 evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next generation HIV maturation inhibitor, as assessed in healthy subjects
Samit Joshi, MD - ViiV Healthcare, United States
 #4
 10:00 AMDiscussion
 
   
10:15 AMMorning Coffee Break & Poster Session I (No. 19 - 36)
   
 Session 3 - Viral Hepatitis & Liver Disease
Chairs: Jennifer Kiser & Alice Tseng 
11:00 AM

Novel antiviral and immune targets to cure HBV
Fabien Zoulim, MD - INSERM, France

 
 11:30 AM

Pharmacological treatment of NASH
Sven Francque, MD, PhD - University Hospital Antwerp & University of Antwerp, Belgium

 
 Special Session: Improving drug delivery for sustained treatment success - Supported by ViiV Healthcare
Chair: Jonathan Schapiro
 
 

 

Opening Remarks
Jonathan Schapiro, MD - Sheba Medical Center, Israel

 
 12:00 PM

Improved long acting drug delivery: What are the technologies?
Andrew Owen, BSc, MSc, PhD, FSB - University of Liverpool, United Kingdom

 
 12:20 PM

Long acting HIV drugs for treatment: Data and potential implementation
Charles Flexner, MD - Johns Hopkins University, United States

 
 12:40 PM

Long Acting HIV Drugs for Prevention: Data and Potential implementation
Laura Waters, MD - Central & North West London NHS Trust, Mortimer Market Centre, United Kingdom

 
  Closing Remarks 
 1:00 PMLunch Break
   
 Session 4 - Drug-drug interactions: evolving challenges
Chairs: Saye Khoo & Angela Kashuba
 2:00 PM

Clinical Case Presentation
Catia Marzolini, PharmD, PhD - University Hospital Basel & University of Liverpool

 
 2:30 PM

ClinicalCasesDDI Website Launch
José Moltó, MD, PhD - Hospital Universitari Germans Trias i Pujol, Spain

 
 Abstract-driven Presentations
 2:40 PMChanges in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website
Sara Gibbons - University of Liverpool, United Kingdom
 #5
 2:55 PMDrugs abuse and chemsex: a new challenge for antiretroviral drug-drug interaction
Tess Martin - APHM La Timone, France
 #6
 3:10 PMEffect of CYP2b6 metabolizer status on levonorgestrel pharmacokinetics when combined with efavirenz-based antiretroviral therapy
Michelle Pham - University Of Nebraska Medical Center
 #7
 Discussion 
   
 3:30 PMAfternoon Coffee Break & Poster Session II (No. 37 - 48)
   
 4:15 PMDebate: Dual maintenance for HIV: Why fix it if it's not broken?
Moderator: Jonathan Schapiro
 
 

Pro Perspective
José Ramón Arribas, MD - Hospital La Paz, IdiPaz, Spain

 
 

Con Perspective
Andrew Hill, MD - University of Liverpool, United Kingdom

 
 Special Lecture
 5:00 PMRegulatory perspective on evaluating ARVs in during pregnancy
Kimberly Struble, PharmD - US Food & Drug Administration, United States
 
   
 7:00 PM Networking Dinner 
   
 

Thursday 16 May

 Session 5 - Special populations and adherence
Chairs: Terrence Blaschke & Tim Cressey
 8:30 AMSpecial Presentation: Infectious disease action plan for the global accelerator for paediatric formulations (GAP-f)
Paul Domanico, PhD - Clinton Health Access Initiative, United States
 #8
 8:45 AMInfant exposure to dolutegravir through placental and breastmilk transfer: A population PK analysis of DolPHIN-1
Laura Dickinson - University Of Liverpool, United Kingdom
 #9
 9:00 AMPharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartum
Jeremiah Momper - University Of California San Diego, United States
 #10
 9:15 AMLow isoniazid concentrations in pregnant and postpartum women treated for tuberculosis irrespective of efavirenz-based ART co-treatment
Marije Van Schalkwyk, MD - Stellenbosch University, South Africa
 #11
 9:30 AMPharmacokinetics of tenofovir alafenamide 25 mg with PK boosters during pregnancy and postpartum
Kristina Brooks, PharmD - University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, United States
 #12
 9:45 AMTenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy
Jenna Yager - University of Colorado, United States
 #13
 10:00 AMAn exploration of adherence measures to detect recent changes in Truvada® dosing patterns
Daijha Anderson - University Of North Carolina Eshelman School Of Pharmacy, United States
 #14
   
 10:15 AMCoffee Break 
   
 11:00 AMShort Poster Presentations; "Best of Posters"
Moderator: Giovanni Di Perri & Marco Siccardi
 Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV
Felix Stader, University Hospital Basel, Switzerland
 #15
 Physiologically-based pharmacokinetic modeling of rilpivirine during pregnancy
Mary Gockenbach - US Food and Drug Administration, Division of Pediatrics and Maternal Health
 #16
 A semi-mechanistic population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: A study of HIV-infected Zimbabwean adolescents
Bernard Ngara - University Of Zimbabwe College Of Health Sciences, Zimbabwe
 #17
 Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of Cabotegravir
Aarti Patel - Glaxosmithkline R&D, United Kingdom
 #18
 The Next 20 Years
Chairs: Charles Flexner & David Burger
 11:30 AM

CRISPR/Cas and gene editing for HIV
Paula Cannon, PhD - University of Southern California Keck School of Medicine, United States

 
 12:00 PM

Owen, Andrew - 2019

Understanding the key determinants of performance for long-acting formulations
Andrew Owen, BSc, MSc, PhD, FSB - University of Liverpool, United Kingdom

 
 Closing Remarks
  

Jennifer Kiser, PharmD
University of Colorado Health Science Center, United States

 
 12:45 PMLunch 

 

PROGRAM

IVHEM 2017 will feature an exceptional program with invited lectures, round table discussions and interactive participation from delegates. The program is published below:

Subscribe to our newsletter to stay up-to-date on IVHEM 2017

 

Friday 17 November 2017

 13:00Welcome 
By the workshop chairs
 13:05Setting the stage - Key challenges in elimination 
Jordan Feld, MD, MPH | Biography
Research Director and Clinician-Scientist, Toronto Centre for Liver Disease, Toronto, Canada
 
 Session 1: Test and screening strategies 
Chairs: Michael Ninburg & Maia Butshashvili
 13:20WHO status report: Global response to the strategic framework;
Yvan Hutin, MD, PhD | Biography
 13:40Global response to the strategic framework; Technologies perspective
Francesco Marinucci, PhD | Biography
Head of HIV/HCV Unit, FIND, Geneva, Switzerland 
 14:00Real-life experiences - Egypt
Imam Waked, MD | Biography
Professor of Medicine, National Liver Institute, Shebeen El-Kom, Egypt
 14:10Real-life experiences - USA 
A. Blythe Ryerson, MD, PhD | Biography
Lead Epidemiologist, Division of Cancer Prevention and Control, Atlanta, GA, USA
 14:20Discussion
 
 15:00Coffee break
 
 Session 2: Care & cure strategies 
Chairs: Jordan Feld & Manal El-Sayed
 15:30Global trends in burden of disease
Graham Cooke, MD, PhD | Biography
Clinician scientist, Imperial College London, London, UK
 15:50How to measure your success; globally and locally 
Yvan Hutin, MD, PhD | Biography 
 16:10Real-life experiences - bottlenecks & hurdles
  Moderators:
  Jordan Feld, MD, MPH | Biography
Research Director and Clinician-Scientist, Toronto Centre for Liver Disease, Toronto, Canada
  Manal El-Sayed, MD | Biography
Professor of Pediatrics, Ain Shams University, Cairo, Egypt
  Panel Members:
  Charles Boucher MD, PhD | Biography
Professor Virology, Erasmus Medical Center, Rotterdam, The Netherlands 
  Maria Cássia Jacintho Mendes Correa, MD | 
Sao Paulo University-Medical School, Brazil
  Margaret Hellard, MBBS, FRACP, FAFPHM, PhD | Biography
Head Centre for Population Health, Burnet Institute, Melbourne, Australia
  Khin Pyone Kyi, MD, PhD | Biography
President of Board of Directors, Myanmar Liver Foundation
  Jeffrey Lazarus | Biography
Copenhagen University Hospital, Denmark
  Olufunmilayo Lesi, FF9WACP, FMCP | Biography
Professor & Head, Gastroenterology and Hepatology Unit, University of Lagos & Lagos University Teaching Hospital, Lagos, Nigeria
  Huma Qureshi, MD | Biography
Pakistan Medical Research Council, Islamabad, Pakistan 
  A. Blythe Ryerson MD, | Biography
Lead Epidemiologist, Division of Cancer Prevention and Control, Atlanta, GA, USA
 17:40Lessons learned - approaches to bottlenecks and hurdles
 
 18:00Networking and poster reception
 19:00Workshop dinner
 

Saturday 18 November 2017

 7:30Early bird coffee
 Session 3: Prevention & screening strategies 
Chairs: Olufunmilayo Lesi & Francesco Marinucci / Ryan Clary
  8:00Prevention transmission strategies on treatment - Pediatric population 
Manal El-Sayed, MD | Biography
Professor of Pediatrics, Ain Shams University, Cairo, Egypt
  8:20Prevention transmission strategies prior to infection - People who inject drugs
Diana Sylvestre, MD | Biography
Executive Director, O.A.S.I.S. Clinic, Oakland, CA, USA
  8:40Prevention transmission strategies prior to infection - Incarceration
Lara Strick MD, MS | Biography
Infectious Disease Physician, Washington Department of Corrections, Turnwater, WA, USA & Clinical Assistant Professor, University of Washington, Seattle, WA, USA 
  9:00Prevention transmission strategies through strengthening the health system 
Maia Butshashvili, MD, MS, PhD | Biography
Health Research Union (HRU)
  9:20Panel discussion
 
 10:00Coffee break
 
 Session 4: Innovative models to finance the health care problem 
Chairs: Margaret Hellard & Charles Boucher
  10:30Poster Presentations
  11:30Medicines Patent Pool’s approach to scale up access to HIV and HCV treatment
Esteban Burrone
Head of Policy, Medicines Patent Pool, Switzerland
 12:00Micro-elimination as a strategy to reach global elimination
Jeffrey Lazarus| Biography
ISGlobal, Hospital Clínic, University of Barcelona
  12:30Closing Remarks
  12:45Lunch

PROGRAM

 

 Thursday, 29 November 2018

  13:30Registration
  15:00Opening remarks
Charles Boucher
Erasmus Medical Center, The Netherlands
 Session 1: Respiratory viruses: Global trends and current challenges
Chairs: Kirsty Short &  Matthias Götte
  15:15Keynote lecture: Current challenges, regulatory considerations, and emerging viruses
Ralph Baric
University of North Carolina, USA
  15:45Plenary Lecture: Opportunities and Challenges for a Broadly Protective Influenza Vaccine
Gary Nabel
Sanofi, USA
  16:05BREAK 
   
 Session 2: Therapeutics against respiratory viruses: Clinical advances &
industry perspective (Non-CME session)
Chairs: Raymond Schinazi & Gary Nabel
  16:25Baloxavir is a first-in-class oral cap-dependent endonuclease inhibitor for treatment of influenza: overview of pre-clinical, phase I and II trials
Takeki Uehara
Shionogi, Japan
  16:45Baloxavir is effective and well tolerated in treating otherwise-healthy and high-risk influenza patients: overview of phase III trials
Andrew Ackrill
Roche, UK
  17:05RV521: A new and potent RSV fusion inhibitor in clinical development
Stuart Cockerill
ReViral, UK
  17:25Cocrystal Pharma: Influenza drug pipeline design
Sam Lee
CoCrystal Pharma, USA
  17:45Discovery and development of novel and potent non-fusion inhibitors of RSV 
Michael Rodin
Enanta Pharmaceuticals, USA
  18:05End of Day 1
  19:00Conference Dinner
   
 

 Friday, 30 November 2018

 Session 3: Basic science, enzymology and respiratory virus inhibition strategies
Chairs: Masaru Kanekiyo & Charles Boucher 
  9:00State-of-the-art lecture: Enzymology of RSV and influenza RdRp  
Matthias Götte               
University of Alberta, Canada
  9:30Difficulties and barriers in developing RSV polymerase inhibitors
Rachel Fearns
Boston University School of Medicine, USA
  9:50Respiratory Syncytial Virus Binds to a Signaling Coreceptor which Induces Recruitment of its Receptor, Nucleolin, to the Cell Surface during Entry 
David Marchant
University of Alberta, Canada
  10:10BREAK 
   
 Session 4: New study models and complications beyond acute respiratory infection
Chairs: David Marchant & Rachel Fearns
  10:40State-of-the-art lecture: Respiratory tract infections and chronic conditions: The case for influenza and diabetes
Kirsty Short
University of Queensland, Australia & Erasmus MC, the Netherlands
  11:103D Human epithelial models to study respiratory virus pathogenesis
Samuel Constant
Epithelix, Switzerland
  Oral Abstract Session 1
  11:30SB 9200 is a novel broad-spectrum antiviral agent effective against both RSV and Flu (#101)
Diane Schmidt                                
Spring Bank Pharmaceuticals, USA
  11:40Structure-based prediction of influenza resistance mutations (#102)
Bryan Cox
Emory University, USA
  11:50Risk factors for RSV severity in immunocompetent and immunocompromised adults presenting in an emergency department (#103)
Slim Fourati                         
Inserm, France
  12:00Evaluation of the therapeutic potential of antibody and T cell targeted immune responses towards RSV small hydrophobic protein (#105)
Genevieve Weir                          
IMV, Inc., Canada
  12:10Panel Discussion
  12:25Lunch & Free Afternoon
  15:15Poster Reception 
   
 Session 5: Immunology and advances in vaccine development
Chairs: Ralph Baric & Asuncion Mejias
  16:00Plenary Lecture: Respiratory syncytial virus pathogenesis & special pediatric populations
Asuncion Mejias
The Research Institute At Nationwide Children’s Hospital, USA
  16:30Nanoparticle display of influenza antigens for development of a universal influenza vaccine
Masaru Kanekiyo
NIH, USA
  16:50Advances in vaccine development against Respiratory Syncytial Virus
Martin Moore
Meissa Vaccines, USA
  Oral Abstract Session 2
  17:10Non-targeted diagnosis of multiple viral infections by means of shotgun metagenomic using deep sequencing  (#104)
Slim Fourati                   
Inserm, France
  17:20mRNA vaccines expressing forms of RSV-F protein are immunogenic and protective in preclinical models of respiratory syncytial virus infection (#106)
Amy Espeseth                                
Merck, USA
  17:30Panel Discussion
  17:45Concluding remarks
Raymond Schinazi
Emory University, USA
  18:00End of Workshop

 

Program

The 13th International Workshop on HIV Transmission will be held as an ancillary meeting to the HIVR4P, taking place from 21-25 October 2018 in Madrid. Their program can be found here

HIVR4P2018_logo

 

Saturday, 20 October 2018

8:30Registration
9:30 Opening
 Session 1: Microbiome and inflammation 
9:40The role of the microbiome and inflammation on HIV transmission
Douglas Kwon, MD, PhD, Ragon Institute of MGH, MIT and Harvard, USA
 Abstract-driven presentation
10:10BV-Associated Bacteria Cause Molecular and Physiological Dysfunction of the Vaginal Epithelium
Alicia Berard
10:20Immune modulatory effects of vaginal microbiota organic acid metabolites on lower female reproductive tract epithelial cells
Gilda Tachedjian
10:30 Genital Inflammation and PrEP effectiveness
Lyle Mckinnon,PhD, Centre for the AIDS Programme of Research in South Africa, South Africa
11:00 Discussion
11:15Group picture & Coffee break
 Session 2: Animal models for prevention
11:45Advances in animal modeling for prevention
Walid Heneine, PhD, Centers for Disease Control and Prevention, USA
 Abstract-driven presentation
12:15A penile model in rhesus macaques to assess pharmacokinetics and characterization of HIV target cells within anatomical compartments of penile tissue
Alison Kohlmeier
12:25In vivo analysis of penile HIV-1 acquisition
Martina Kovarova
12:35 Post-exposure prophylaxis with single doses of combination EVG/COBI/FTC/TAF protect macaques against Rectal SHIV Infection
Ivana Massud
12:45Discussion
13:00 Lunch Break
14:15 Leveraging antibody-mucin interactions to enhance vaccine function 
Thomas Hope. PhD, Northwestern University, USA
 Session 3: Abstract driven presentations
14:45Transmitted/Founder Virus-Like Variants are Archived in the Reservoir
Kelsie Brooks
14:55Comparison of genetic sequences from donor and recipient viruses from linked subtype A transmission pairs
Samantha Mcinally
15:05HIV, HBV and HCV infection and linkage to care in migrants: The Immigrant Take Care Advocacy (I.Ta.C.A.) experience in Palermo
Maurizio Milesi
15:15Discussion
15:40Coffee break
 Session 4: The future of prevention
16:15Where are we with long-acting treatment?
David Margolis, MD, MPH, ViiV Healthcare, USA
16:45Where are we with long-acting PrEP?
Leah Johnson, PhD, RTI International, USA
17:15Where are we with bNAb strategies?

Devin Sok, PhD, International AIDS Vaccine Initiative, USA

17:45 Discussion
18:00 Closure
18:15Poster viewing and reception 
19:30Workshop Dinner

 

Program

 

  

 

Tuesday 22 May 2018

 16:00Opening Of the Workshop
Conference Chair 
 Session 1: New Technologies and formulations
 16:15Lecture on new Injectables and the effect of having no liver passage   
xxx
yyy, USA
 16:45Guidelines of the FDA
xxx
yyy,  United Kingdom
 17:15

Pharmacology of Modified Moabs
xxx
yyy, Thailand

 17:45Discussion
 
 10:15Break
 
 Session 2: 
 16:30Clinical Implementation of Pharmacogenomics 
xxx
yyy, USA
 17:45Abstract Presentation 
xxx
yyy,  United Kingdom
 16:45Abstract Presentation 
xxx
yyy,  United Kingdom
 17:15

Abstract Presentation
xxx
yyy, Thailand

 17:15

Discussion

 
  18:00Welcome Reception & Poster Viewing Session I
  
 16:00Break
  
 18:30Workshop dinner
 
 

Wednesday 23 May 2018

 8:00Morning coffee
 Session 3: Hepatitis related topic
 8:30The use of DAA's in pregnancy in HCV infected mothers
TBA
UNICEF, USA
 9:00Clinical case presentation
TBA
Texas Children's Hospital, USA
 9:30Abstract presentation xxx
TBA
 9:45Abstract presentation xxx
TBA
 10:00Discussion
 10:15Break
 
 10:40Break
 
  
 Session 4: 
 11:10Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants
Mark Mirochnick MD,
Boston University, USA
 11:40Short oral poster presentations 
 11:55Discussion
 
 12:10Lunch & Poster Viewing
 
 10:15Break
 
 Session 5: Adolescents
 13:30Young investigator award
 13:45The emerging pediatric population:  youth with behaviorally-acquired HIV 
Sarah Bernays, PhD,
The University of Sydney, Australia
 14:15Preventing HIV in young women in Africa – the importance of social protection
Lucie Cluver, PhD,
University of Oxford / University of Cape Town, UK / South Africa
 14:45Oral Abstact Presentations
 15:45Break
 
  
 Session 6: 
 16:15HIV self-testing – should this be promoted for youth? Short talk and panel of researchers and youth
TBC
 16:30Discussion with speakers, adolescents and audience
 17:00Closing
 

 

Program

The 5th edition of the International HBV Cure Workshop featured the world's most prominent and distinguished speakers that discussed the most current and trending issues in the field. 

 

 Wednesday 7 November

 8:00Welcome
 Session 1: Modulating approved therapies to achieve HBV Cure
 8:05What is the cure rate with current therapies?
Harry Janssen
Toronto General Hospital / University Health Network, Toronto, Canada
 8:20Stopping Nucleos(t)ide Analogues:  When is it beneficial, when is it dangerous? 
Thomas Berg
University of Leipzig, Germany
 8:35Immune reconstitution with current available antiviral therapies: a baseline to gauge new immunotherapies.
Andre Boonstra
Erasmus Medical Center, Rotterdam, The Netherlands
 8:50Discussion
   
 9:30COFFEE BREAK
   
 Session 2: New Endpoints and Biomarkers
 10:00What are the pros and cons of HBsAg loss as the endpoint for treatment?
Jordan Feld
Toronto Centre for Liver Disease, Toronto, Canada
 10:15Can we measure (activity of) cccDNA in the blood?
Massimo Levrero
INSERM, Lyon, France
 10:30Will HBsAg depletion restore HBV specific immunity?
Adam Gehring
Toronto Centre for Liver Disease, Toronto, Canada
 10:45Discussion
   
 11:25SHORT BREAK
   
 Session 3: Update on Immune Targets for HBV Therapy 
 11:35Rationale for modulating innate immunity: TLR, RIG- and others.
Mala Maini
University College London, London, UK
 11:50Antiviral effect of the RIG-I agonist, Inarigavir
Nezam Afdahl
Beth Israel Deaconess Medical Center, Boston, USA
 12:00Activating Toll-like receptor (TLR)-8 with GS-9688 for HBV therapy
Simon Fletcher 
Gilead Sciences, Foster City, USA
 12:10Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model
Lu Gao
Roche Innovation Center Shanghai, Shanghai, China 
 12:20Innate activation with Inactivated parapox viruses for HBV therapy - AIC649
Daniela Paulsen
AiCuris, Germany
 12:30LUNCH
 13:30Rationale for Modulating Adaptive Immunity: Therapeutic Vaccination, Checkpoint Inhibitor and others
Robert Thimme
University of Freiburg, Freiburg, Germany
 13:45Anti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection
Daniel Verdon
University of Auckland, Auckland, New Zealand
 14:00Discussion
   
 14:45COFFEE BREAK
   
 Session 4: Update on Virologic Targets for HBV Therapy
 15:15Rationale for different Virological Targets in HBV
Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
 15:30Clinical progress of the entry inhibitor Myrcludex B
Stephan Urban
University of Heidelberg, Heidelberg, Germany
 15:45Establishing functional control of HBV and HDV infection with REP 2139-based combination therapy
Andrew Vaillant
Replicor, Montreal, Canada
 15:55Clinical update on reducing HBV virus and antigen production using RNAi
Bruce Given,
Arrowhead, Pasadina, USA
 16:05Clinical update, antiviral effect and mode of action of capsid assembly modulators
Jeysen Yogaratnam
Janssen Biopharma, South San Francisco, USA
 16:15Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates
Rich Colonno,
Assembly Bioscience, San Francisco, USA
 16:25Roundtable
   
 17:00Closure of the Workshop

 

Program

HIV Pediatrics will feature an exceptional program with invited lectures, round table discussions and interactive participation from delegates. The program is published below:

 

 

Friday 20 July 2018

 08:30Opening words
Lynne Mofenson & Sibyl Geelen 
 08:45Social opening/video 
Sibyl Geelen, MD, PhD
 
 Session 1: Pediatric Care and Treatment
 09:00Early treatment and clinical outcomes – does early ART make a difference?   
Louise Kuhn, PhD
Columbia University Medical Center, USA
 09:15Controllers: post-treatment vs elite controllers – what do we know?
Phillip Goulder, MA, FRCPCH, DPhil, FMedSc,
University of Oxford,  United Kingdom
 09:30

HIV vaccines and broadly neutralizing monoclonal antibody - role in the cure agenda
Sandhya Vasan, MD
Armed Forces Research Institute of Medical Sciences/ US Military HIV Research Program, Thailand

 09:45Roundtable: Talking with parents and children/youth about cure research
 
 10:15Break
 
  10:45Debate: All children should be switched to dolutegravir-based ART regimens 
CON
Nandita Sugandhi, 
Columbia University, USA 
PRO
Adeodata Kekitiinwa, MBChB, MMed
Baylor College of Medicine, Uganda
  11:15Oral Abstract Presentations
 
  12:30Lunch & Poster Viewing
 
  14:00Mobile technology for engaging children and youth in treatment and prevention
Lisa Hightow-Weidman MD, MPH,
University of North Carolina at Chapel Hill, USA
 
 Session 2: Comorbidities/infections
 14:30Challenges and successes in implementing rapid infant diagnostic testing 
Patricia Fassinou, MD
Elizabeth Glaser Pediatric AIDS Foundation, Cote d’Ivoire
 15:00Oral Abstract Presentations
 
 16:00Break
 
  16:30Clinical case presentations 
Moderators: Gareth Tudor Williams & Moherndran Archary 
  High Income
Henriette Scherpbier, MD 
Emma Childrens Hospital / Academic Medical Center/ University of Amsterdam
Jason Brophy, MD
Children's Hospital of Eastern Ontario, USA
  Low Income
Tavitiya Sudjaritruk, MD, ScM, PhD,
Chiang Mai University Thailand
Grace McHugh, MBBCh, MRCPI,
Biomedical Research and Training Institute, Zimbabwe
  17:15Short oral poster presentations 
  17:30 Poster Viewing and Welcome Reception
 
 18:30Workshop dinner
 
 

Saturday 21 July 2018

 8:00Morning coffee
 Session 3: Prevention of Mother-to-Child Transmission
 8:30Current implementation
Shaffiq Essajee, MD,
UNICEF, USA
 8:40Malawi
Maria Kim, MD,
Texas Children's Hospital, USA
 8:50Zimbabwe
TBC
 9:00Discussion
 9:10Debate: All infants should receive oral antiretroviral prophylaxis throughout breastfeeding 
CON
Amy Slogrove,MB ChB, MMed, PhD,
Stellenbosch University, South Africa
PRO
Philippe van der Perre MD, PhD
University Montpellier France
 09:40Oral Abstract Presentations
 
 10:40Break
 
 11:10Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants
Mark Mirochnick MD,
Boston University, USA
 11:40Short oral poster presentations 
 11:55Discussion
 
 12:10Lunch & Poster Viewing
 
 
 Session 4: Adolescents
 13:30Young investigator award
 13:45The emerging pediatric population:  youth with behaviorally-acquired HIV 
Sarah Bernays, PhD,
The University of Sydney, Australia
 14:15Preventing HIV in young women in Africa – the importance of social protection
Lucie Cluver, PhD,
University of Oxford / University of Cape Town, UK / South Africa
 14:45Oral Abstact Presentations
 15:45Break
 
 16:15HIV self-testing – should this be promoted for youth? Short talk and panel of researchers and youth
TBC
 16:30Discussion with speakers, adolescents and audience
 17:00Closing
 

 

Program

 

The 2019 program consisted of the following sessions.

  • capacity-building sessions,
  • state-of-the-art lectures,
  • debates,
  • panel discussion sessions,
  • abstract presentations,
  • poster discussion sessions,
  • guided poster walks, and
  • poster viewing sessions.

Program

 Click here for the full Program including abstract presentations.

 

Thursday 11 October - Day 1

9:00 Opening of the Workshop
 Session 1: Epidemiology of HIV and hepatitis in the CEE countries
9:10Epidemiology of HIV Infection and Treatment in Europe
Teymur Noori, ECDC, Stockholm, Sweden
9:35Update on changes in Hepatitis B and C in CEE countries
Milosz Parczewski, MD, PhD, Pomeranian Medical University, Sczeczin, Poland
10:00How can new diagnostics help to increase the number diagnosed?
Elena Ivanova, MD, PhD, FIND, Geneva, Switzerland
10:25 Country models: what has and what hasn’t worked
Nikoloz Chkhartishvili, MD, MS, PhD, Infectious Diseases, AIDS And Clinical Immunology Research Center, Tbilisi, Georgia
Zahedul Islam, MBA, Alliance for Public Health, Kiev, Ukraine
10:45

Round table Discussion
All chairs and invited speakers

11:10Poster Viewing Session (Posters Nr. 12 - 23) with Coffee and Refreshments
 Session 2: Challenges in HIV and Viral Hepatitis
11:40Hepatitis Delta: what are the new developments, what are the challenges?
Cihan Yurdaydin, MD, Ankara University Medical Centre, Ankara, Turkey
12:05HIV & women's health: do we have any game changers here?
Mariana Mardarescu, MD, PhD, Institute for Infectious Disease M. Bals, Bucharest, Romania
12:30 Round table discussion
12:45 Group picture and Lunch
 Special session: Improving care of treatment-experienced patients
13:45Approach to managing treatment-experienced patients
Jonathan Schapiro, MD, Sheba Medical Center, Tel Aviv, Israel
14:00 

Utilizing new diagnostics, web-tools and drugs for optimal care of treatment-experienced patients. A case-based joint presentation
Jonathan Schapiro, MD, Sheba Medical Center, Tel Aviv, Israel
David Back, PhD, University of Liverpool, Liverpool, United Kingdom

14:15 Treatment-experienced patients in Central and Eastern Europe – What needs to be done?
Viktor Aster, MD, PhD, Charles University, Prague, Czech Republic
14:30 Discussion
 Session 3: Switching HIV therapy: considerations and strategies
14:45 Clinical considerations in switching antiretroviral therapy
David Jilich, MD, HIV Centre Prague, Prague, Czech Republic
15:05Clinical Case Discussion: Switching HIV Therapy
Pavel Khaykin, MD, MainFachArzt, Frankfurt, Germany
15:25Discussion
15:35Poster Viewing Session (Posters Nr. 24 - 35) with Coffee and Refreshments
 Session 4: Abstract-driven presentations
16:05Real-life effectiveness of ledipasvir/sofosbuvir regimen and factors associated with retention in care among HIV/HCV co-infected PWID in Ukraine
Tetyana Kyrychenko, Ukraine
 #1
16:15Possible misclassification of HIV transmission between men:  results of phylogenetic analysis
Natia Dvali, Georgia
 #2
16:25Epidemiology of HIV in the Baltic countries (Estonia, Latvia, Lithuania)
Saulius Caplinskas, Lithuania
 #3
16:35Socio-demographic risk factors for high HEV seroprevalence among liver transplant recipients in Croatia
Anna Mrzljak, Croatia
 #4
16:45Spontaneous HCV clearance in HCV/HIV coinfected patients from AIDS Center Prague
Viktor Aster, Czech Republic
 #5
 17:00Industry-sponsored Symposium
 18:00End of day 1
 18:15Departure for the boat
 19:15Workshop Dinner, Klub Lavka - Charles Bridge (pre-registration required)
 

Friday 12 October - Day 2

 8:30Industry-sponsored Symposium
  
 Session 5: Management of hepatitis C
9:30 Critical assessment of the global epidemiology of HCV (how reliable is the global HCV prevalence data)
Peter Ferenci, MD, University of Vienna, Vienna, Austria
09:55 Liver transplantation for HCV and HBV in The Czech Republic
Soňa Fraňková, MD, PhD, IKEM Prague transplant center, Prague, Czech Republic
10:20

Case Study: The changing IV drug use problem/pattern and what that means to the epidemic
Mojca Maticic, MD, PhD, University Medical Centre Ljubljana, Ljubljana, Slovenia

10:45The EpiTer-2 database
Robert Flisiak, MD, PhD, Medical University of Bialystok, Bialystok, Poland
11:05Discussion
11:15Poster Viewing Session (Posters Nr. 36 - 47) with Coffee and Refreshments
 Session 6: Management of hepatitis B
11:45Hepatitis B cure strategies: how far are we?
Heiner Wedemeyer, MD, University Clinic Essen, Essen, Germany
 Abstract-driven presentations
12:10Mortality and causes of death among HIV/HCV co-infected persons in the Eastern European country of Georgia
Akaki Abutidze, Georgia

 #6

12:20HCV resistance-associated variants among HCV treatment naïve HIV-coinfected patients in Ukraine. A pilot study
Marta Vasylyev, Ukraine
 #7
12:30Lunch
 Session 7: Hot topics in HIV and hepatitis
13:30New delivery systems and long acting antiretroviral drugs
David Back, PhD, University of Liverpool, Liverpool, United Kingdom
13:55HIV PreP
Pep Coll, MD, AIDS Research Institute Irsi Caixa, Badalona, Spain
 Abstract presentations
14:20Early results of pre-exposure prophylaxis program in Georgia
Nikoloz Chkhartishvili, Georgia
 #8
14:30The Regression of Liver Fibrosis in HCV Cirrhotic Patients Who Registered SVR after DAA Therapy
Anca Leustean, Romania
 #9
14:40

Approaches to providing hepatitis C viremia testing to people who inject drugs in Georgia
Maia Japaridze, Georgia

 #10
14:50Insulin-like growth factor and platelet-derived growth factor in liver cells of patients with chronic hepatitis C at different stages of fibrosis
Igor Tikhonov, Russia
 #11
15:00End of meeting

 

 

 

 

 

Program

Click here for the full program including abstract presentations.

Thursday 13 September - Day 1

8:30 Opening of the workshop
Session 1: The geriatric assessment and interventions - part 1
Chair: David Moore
8:40Comprehensive geriatric assessment
Alison Moore, MD, MPH, FACP, AGSF, University of California San Diego, USA
9:10Cognitive Aging in the Era of Effective Antiretrovirals
Leah Rubin, PhD, MPH, Johns Hopkins University, Baltimore, Maryland, USA
9:40Abstract driven presentations
10:15Coffee break
Session 2: The geriatric assessment and interventions - part 2
10:45Translating Exercise Interventions into the Community with Adults Aging with HIV
Kelly O'Brien, PhD, PT, University of Toronto, Canada
11:15Polypharmacy
Catia Marzolini, PharmD, PhD, University Hospital Basel,  Switzerland
11:45Abstract driven presentations
12:15 Roundtable discussion
12:45 Lunch
Session 3: Mitochondrial medicine
Chair: Julian Falutz
13:45Mitochondrial dysfunction in aging
Brendan Payne, PhD, Newcastle University, U.K
14:15Atherosclerosis in HIV: Insights into Biology, Detection and Management
Ahmed Tawakol, MD, Massachusetts General Hospital, Boston, USA
14:45Abstract driven presentations
15:15Discussion
15:30Coffee Break
Session 4: Immunity and aging
Chair: Charles Flexner
16:00Immunity and Aging: Impact of HIV infection
Savita Pahwa, MD, University of Miami, Florida, USA
16:30Abstract driven presentations
17:00Discussion
17:15Welcome drinks and poster viewing session 1
19:00Workshop dinner (on pre-registration only)

Friday 14 September - Day 2

Session 5: Metabolic dysfunction and cognition
Chair: Scott Letendre
8:30Metabolic dysfunction and cognition
Norman Haughey, PhD, Johns Hopkins University, Baltimore, MD, USA
9:00 Abstract driven presentations
10:00Discussion
10:15Coffee break and poster viewing session 2
Session 6: Frailty and sarcopenia
Chairs: Kristine Erlandson and Cara Wilson
11:00Identifying presymptomatic biomarkers for functional decline in people aging with HIV infection
Monty Montano, PhD, Harvard University, Boston, Massachusetts, USA
11:30HIV and the Geriome: Linking Gut Dysbiosis to Inflammation
Cara Wilson, MD, University of Colorado, USA
12:00Abstract driven presentations
12:30Discussion
12:40Lunch

Session 7: Menopause in HIV+ women
Chair: Jonathan Schapiro

13:45Considerations for the HIV-positive woman during menopause 
Sharon Walmsley, FRCPC, MD, MSc, University Health Network, Toronto, Canada
14:15Abstract driven presentations
14:45Discussion
Session 8
 15:00 Update from NIH
Maureen Goodenow, PHD, Office of AIDS Research (OAR), USA
 15:30 Roundtable discussion: policy makers perspective, patients perspective
 16:15 Closure of the workshop
  
  

 

 INVITED SPEAKERS

Program

To download or print the final program, download here: ICASA Symposium - Final Program 
For speaker's bio's, please click on names

Wednesday 6th December 2017

18.15 Registration and Welcome coffee/snacks
18.45 Introduction by the chairs

 18.50

 The Future ART in Africa

  • Which ART are currently used in most African countries?
  • Global milestones with ART regimens with the aim of simplifying efficacy (All drugs work, the need for CD4 monitoring, need for Viral load monitoring, need for resistance testing) If the right drug is used, only Viral load monitoring may be needed 

Fransçois Venter 

 19.10

 Simplifying ART Adherence

  • Clinical overview of Single Tablet Regimens (STRs)
  • Results of studies as regard to efficacy, failure and resistance development 

Mark Nelson, MD 

 19.30

 Simplifying Toxicity Monitoring 

  • Requirements for monitoring 
  • Toxicity and the impact of limited monitoring 
  • Advent of new toxicities with time 

Lloyd Mulenda (Zambia) 

 19.50

 What does simple therapy mean to me? (Patient experience)

Kenley Sikwese (Zambia) 

20.05 

Round table discussion & Summary

 20.25 Closing Remarks
  

 

Program

The Organizing Committee of the 1st International Conference on (Re-)Emerging Infectious Diseases is currently working hard on finalizing the conference program.

Below you will find the preliminary program. Please note that this program is subject to change. The final program will be announced shortly and will be made available on this website.

 

Day 1 -  Patterns of Emerging Diseases

 10:00Walk in coffee
 10:30 Opening of the conference 
  Session 1: Forward looking based on past experiences
 10:45General Overview on Emerging Infections globally 
 11:15Emerging infections on the African continent - The pathogen
 11:45Emerging infections on the African continent - The public health response
 12:15Panel discussion: Is the world prepared?
  Session 2: Factors facilitating outbreaks
 14:00Human - Animal contact
 14:30Impact climate change 
 15:00Migration
 15:30Discussion
 Session 3
  16:30 - 17:15Invited lectures
  17:30Discussion
  19:00Welcome reception
 

Day 2 - Managing the (re-)emerging infections 

  Session 4: Managing (re-)emerging bacterial infections - Prevention
 8:30 Potential Topic for a lecture - Surveillance / Vaccine development
 9:00 - 9:30Abstract presentation/ Real life examples
 9:45Panel discussion 
  Session 5: Managing (re-)emerging bacterial infections - Control
 11:00What's new in Antimicrobial Resistance
 11:30Clinical case presentation: Multidrug resistant TB 
 11:45Abstract - Real life examples
 12:00Discussion
 12:30Poster viewing session 
 Session 6: Managing (re-)emerging viral infections - Prevention
 14:30The new epidemic of Drug Resistant HIV-1
 15:00 - 15:15Abstract - Real life examples
 15:30Discussion
 Session 7: Managing (re-)emerging viral infections - Control
 16:30Zika: Where has it gone to?
 17:30Panel discussion
 18:45Workshop dinner
 

Day 3 - Innovations for control

  Session 8: Lessons learned 
 8:30 On the ground experience
 9:00 - 9:30How can we manage the 'Panic'
 9:45Advancing the science agenda in Africa for public health?E-tools to fight the outbreak: where do they come in?
 10:00Discussion
  Session 9: How do we keep up during the outbreak? 
 11:00Ultra-rapid diagnostic testing
 11:30Fast track development of Vaccines/drugs/treatment options
 12:00Round table Discussion: What is needed to control the next outbreak?
 Session 10: Public health issues 
 13:30Where do we get the money
 14:00How do we secure care for other diseases during an outbreak
 14:30Panel discussion

 

Program

Wednesday 18 October

 
   Session 1: Clinical Update on HBV Cure
8:30Workshop Opening & HBV update
Workshop Chairs
8:35TAF – The latest update, which questions remain to be answered?
Pietro Lampertico
, MD, PhD
University of Milan, Milan, Italy
8:50Hepatitis B Cure: From Discovery to Regulatory Endpoints in HBV clinical research: A summary of the AASLD/EASL statement
Fabien Zoulim
, MD, PhD
INSERM, Paris, France
9:05Is immunomodulation really needed to cure HBV?
Harry Janssen,
MD
Toronto Center for Liver Disease, Toronto, Canada
9:20Discussion
 
9:40Coffee break
 
   Session 2: New biomarkers: how will they help us?
10:10How to use new virological biomarkers to assess HBV cure: quantitative HBsAg, HBcrAg, HBV-RNA
Florian Bömmel,
MD
University of Leipzig, Leipzig, Germany
10:25To look inside or outside of the liver for evidence of HBV cure?
Georg Lauer,
MD, PhD
Massachusetts General Hospital Boston, MA, USA
10:40Discussion
 
   Session 3: Latest update on New Treatment modalities - Immunologic response
11:00How does HBV interact with the immune system
Mala Maini
, MD, PhD
University College London, London, United Kingdom
11:15Innate Immunity : TLR, RIG-I, STING and potential others
Adam Gehring
, PhD
University of Toronto, Toronto, Canada
11:30Adaptive Immunity: Therapeutic vaccination, checkpoint inhibition and potential others
Andre Boonstra,
PhD
Erasmus Medical Center, Rotterdam, the Netherlands
11:45Panel Discussion
 
12:15Lunch
 
   Session 4: Latest update on New Treatment modalities - Virologic update
13:15Entry inhibition
Stefan Urban, 
PhD
Heidelberg University, Heidelberg, Germany
13:25CCC – DNA inhibition
Anuj Gaggar
MD, PhD
Gilead Sciences, Foster City, USA
13:35RNA interference
Bill Symonds,
PharmD
Arbutus, Burnaby, Canada
13:45Capsid inhibition
Angela Lam, 
PhD
Janssen, USA
13:55HBV Ribonuclease H
John Tavis
, PhD
Saint Louis University School of Medicine, Saint Louis, MO, USA
14:05Other virological mechanisms
Stephen Locarnini, BSc, PhD, MBBS, FRCP
Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
14:15Round table discussion
 
15:00Coffee break
 
   Session 5: From the science to the clinic
15:30Is personalized therapy needed to achieve success?
Marion Peters
MD
University of California San Francisco, San Francisco, CA, USA
15:50Combination therapy how to navigate in a minefield of efficacy and toxicity?
Jordan Feld
, MD
Toronto Centre for Liver Disease, Toronto, Canada
16:10Innovative trial design
Henry Lik Yuen Chan
, MD
Chinese University of Hong Kong, Hong Kong
 
16:30Round table discussion:
Trial design, treatment endpoints and regulatory approach
Bill Symonds
, PharmD - Arbutus, Canada
Jeffrey Murray, MD, MPH - U.S. Food and Drug Administration, USA
Fabien Zoulim, MD, PhD - INSERM, France
Henry Lik Yuen Chan, MD - Chinese University of Hong Kong, Hong Kong
Marion Peters, MD - University of California San Francisco, USA
Pietro Lampertico, MD, PhD - University of Milan, Italy
17:30Closure of workshop

 

Program

Break

SUNDAY, DECEMBER 3, 2017

OPENING SESSION
 15:00

Opening Remarks: Science Drives Success
Raymond F Schinazi
Emory University

INVESTING IN A CURE: No One Creates Success Alone
Chairs: Ana Lok, Michigan University, USA - Hélène Strick-Marchand, Pasteur, France
 15:10Plenary Presentation
Eliminating Hepatitis C by 2030 -  Enhancing Prevention Care and Treatment Among People who Inject Drugs
Margaret Hellard
Monash University, Australia
 15:50Strategy for the Elimination of Hepatitis B and C (Academy of Medicine Report)
Andrew Aronsohn
University of Chicago, USA
 16:10Elimination of HCV: The DC Story
Henry Masur
NIH, USA
 16:30The French and European Approach Towards Hepatitis Elimination
Tarik Asselah
Hôpital Beaujon, France
 16:50Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Ana Lok
Michigan University, USA
 17:10Global Strategies to Eliminate Hepatitis B (ICE-HBV)
Peter Revill
Victorian Infectious Diseases Reference Laboratory, Australia
 
ORAL ABSTRACT SESSION I
 17:20

Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drugs (PWID) in the United States (US): a mathematical model using data from the C-EDGE CO-STAR Study
Michael Robertson, Merck, USA

 17:40

Novel Nucleosides, CMCP and CFCP, Potently Block the Infectivity and Replication of Wild-type and Drug-resistant HBVs in Culture and in Human-liver-chimeric Mice and Show Potential QW or Q2W (64)
Hiroaki Mitsuya, National Institutes of Health, USA

 
17:50Welcome Reception
 

MONDAY, DECEMBER 4, 2017

DISCOVERIES AND ADVANCES IN HEPATITIS RESEARCH
Chairs: Francis Chisari; The Scripps Research Institute, USA - Harvey Alter; National Institutes of Health, USA
 8:00Introduction and Presentation of the William H. Prusoff HEP DART Lifetime Achievement Award
Raymond F. Schinazi
Emory University
 8:10Introduction by Joan Block
 8:20William H. Prusoff HEP DART Lifetime Achievement Award Lecture:
Access to HIV, HBV, and HCV Antiviral Agents Globally 

John Martin
Gilead Sciences, USA
 
PROSPECTS FOR A CURE
Chairs: Jake Liang, National Institutes of Health, USA - Jeffrey Glenn, Stanford University, USA
 9:00Plenary Presentation
Liver Disease in Chinese-perspective from a Hepatologist
George Lau
Humanity & Health Medical Group, Hong Kong
 9:40DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination
Jason Grebely
University of New South Wales, Australia
10:00Break
 10:30Short Duration DAA HCV Therapy: How Short Can We Go?
Shyamasundaran Kottilil
University of Maryland, USA
 10:50A Tale of Two Viruses: HBV and HCV Co-Infection
Jake Liang
NIH, USA
 11:10The Global Burden of Non-Alcoholic Steatohepatitis
Zobair Younossi
Inova Health System, USA
 11:30Special Lecture
Hepatitis B/C and NASH: Crossroads Between Science and Business

Geoffrey Meacham
Barclays Biotech/Pharma Research, USA
12:00Panel Discussion
 
ORAL ABSTRACT SESSION II
12:20

Elucidating the structural and dynamic mechanism of resistance for clinically relevant variants against HCV NS3/4A protease inhibitors
Ashley Matthew; University Of Massachusetts Medical School, USA

 12:30

Real-world utilization and effectiveness of elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada: Z-PROFILE study
Edward Tam; Merck Canada Inc., Canada

12:40Lunch
 
HEPATITIS B VIRUS: BASIC SCIENCE
Chairs: Fabien Zoulim, University of Lyon, France - Stephen Locarnini; Victorian Infectious Diseases Reference Laboratory, Australia
 15:30Plenary Presentation
Catch Me If You Can – Tuning Immunity for HBV Cure

Ulrike Protzer
Technical University of Munich, Germany
 16:10Immunology of HBV
Adam Gehring
Toronto Centre for Liver Disease, Canada
 16:30Optimizing Infection Systems and Screens and Studying Innate anti-HBV Factors and Mechanisms
Lefteris Michailidis
Rockefeller University, USA
 
16:50Break
 
THE PATH AHEAD: HEPATITIS B RESERVOIRS, CONTROL AND ELIMINATION
Moderators: Mark Sulkowski; The Johns Hopkins University, USA - Raymond F. Schinazi; Emory University, USA
 17:20Special Lecture
Personalized Approaches to HBV Cure

Marion Peters
University of California, USA
 Debate: Is Host Genome Integrated HBV Relevant?
 17:50The Con Perspective
Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory, Australia
 18:10The Pro Perspective
Christian Brechot
Global Virus Network, USA
 18:30Panel Discussion
 
19:20Adjourn
 

TUESDAY, DECEMBER 5, 2017

TARGETS, MODELS, THERAPIES AND CURES FOR HEPATITIS VIRUS
Chairs: Eugene Schiff, University of Miami, USA - Ulrike Protzer; Technical University of Munich, Germany
8:00Plenary Presentation
Endpoints and New Targets for Curing Hepatitis B
Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory, Australia
8:40Targeting the HBV-Macrophage-Stellate cell axis to treat HBV-induced Liver Diseases
Lishan Su
University of North Carolina at Chapel Hill, USA
9:00Core Antibody: anti-HBc What is the Core of the Story?
Robert Gish
Hepatitis B Foundation, USA
9:20Development of Immune Competent Small Animal Models for HBV
Hélène Strick-Marchand
Pasteur Institute, France
9:40Panel Discussion
 
ORAL ABSTRACT SESSION III
 10:00

In vivo evaluation of anti-HBV CRISPR/Cas9 Therapy in the FRG mouse
Keith Jerome; Fred Hutchinson Cancer Research Center, USA

 10:10

A Novel Immunotherapy for Chronic HBV and HDV Infections that Bypass Tolerance and Induce Broadly Crossreactive and Neutralizing Antibodies
Matti Sallberg; Karolinska Institutet, Sweden

 
10:20Break
 

RESISTANCE, CELL BIOLOGY AND OTHER HEPATITIS VIRUSES
Chairs: Tarik Asselah; Hôpital Beaujon, France -
Paul Pockros, Scripps Translational Science Institute, USA

10:40Plenary Presentation
Revisiting the Molecular and Cell Biology of the Hepatitis B Virus Towards Elimination
Fabien Zoulim
University of Lyon, France
 11:20Distinct cellular entry pathways for quasi-enveloped and naked hepatitis A virions 
Stanley Lemon
University of North Carolina at Chapel Hill, USA
 11:40Emerging Therapeutic Targets and Concepts for Delta Hepatitis Virus
Jeffrey Glenn
Stanford University, USA
 12:00HEV Update: Diagnostics and Management
Kenneth Sherman
University of Cincinnati, USA
 12:20Panel Discussion
 
12:30Lunch
 

LOOMING CHALLENGES AND QUESTIONS IN HBV CURE
HEPATITIS B FOUNDATION SESSION:
Chairs: Marion Peters, University of California, San Francisco - Timothy Block; Hepatitis B Foundation, USA

 A Round Table Discussion - Looming Challenges and Questions in the Cure for Chronic Hepatitis B
  
 13:30Introduction
 13:35Is There a Best Direct Acting Antiviral in Development?
Fabien Zoulim; University of Lyon, France
 13:47Is There a Best Host Acting Antiviral in Development?
Jake Liang; National Institutes of Health, USA 
 13:59Is There a Best Immunomodulator in Development?
Ulrike Protzer; Technical University of Munich, Germany
 14:10Discussion by Panel and Audience
 14:30Closing Remarks
 
EVENING SESSION
 15:30Poster Session
 17:00Review of Poster Presentations
Adrian Ray; Gilead Sciences, USA
Harvey Alter; National Institutes of Health, USA
 
SHIFTING TIDE OF DRUG DEVELOPMENT TOWARDS HBV, NASH, AND HCC: BATTLING GIANT KILLERS
Chairs: Kenneth Sherman; University of Cincinnati, USA - Stanley Lemon; University of North Carolina at Chapel Hill, USA
 17:50New directions towards functional cure of Chronic Hepatitis B
Lawrence Blatt
Janssen, USA
 18:10Looking back to move forward: designing next-gen RNAi for best results in HBV
Bruce Given
Arrowhead Pharmaceuticals, USA
 18:30SB 9200: A novel RIG-I agonist for chronic hepatitis B 
Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory, Australia
 18:50Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure 
Michael Sofia
Arbutus Biopharma, USA
 19:10Immunotherapy is coming for HCC 
Spiros Hiotis
Mount Sinai Hospital, New York, USA.
 19:30Studies of the HBV-immune modulator AIC649
Helga Rübsamen-Schaeff
AiCuris, Germany
 
 
19:50Adjourn
 

WEDNESDAY, DECEMBER 6, 2017

HEPATITIS C VIRUS – Part 1: THE BAR HAS BEEN RAISED TO 98% SVR
Chair: George Lau; Humanity and Health Liver Clinic, Hong Kong - Charles Boucher; Erasmus University, The Netherlands
 8:00Plenary Presentation
Clinical Challenges in HCV infection
Mark Sulkowski
Johns Hopkins University, USA
 8:40Eliminating HCV Transmission by Enhancing Care and Treatment Among HCV/HIV Co-infected Individuals in Australia
Joseph Doyle
Monash University, Australia
 9:00Management of HCV in Decompensated liver disease
Michael Manns
Hannover Medical School, Germany
 9:20When are we done? How long do we follow patients with advanced fibrosis or cirrhosis after SVR?
Paul Pockros
Scripps Translational Science Institute, USA
 9:40Panel Discussion
 
10:00Break
 
HEPATITIS C VIRUS - Part 2
Chair: 
Margaret Hellard; Monash University, Australia - Michael Fried; University of North Carolina at Chapel Hill, USA
 10:20Plenary Presentation
DAA Controversies: Do they Cause HBV Reactivation and/or HCC?
Jordan Feld
Toronto General Hospital, Canada
 11:00Pan-genotypic direct-acting antiviral agents: Opportunity to achieve HCV elimination
Tarik Asselah
Hôpital Beaujon, France
 11:20Update on Merck’s HCV Program  
Michael Robertson
Merck, USA
ORAL ABSTRACT SESSION IV 
 11:40

Long term follow-up after Treatment with Ombitasvir/Paritaprevir/ritonavir ± Dasabuvir ± Ribavirin in the AMBER – Real World Experience Study
Robert Flisiak, Medical University of Bialystok, Poland

 11:50

A Next Generation HBV Capsid Inhibitor, AB-506: In Vitro and In Vivo Antiviral Characterization (67)
Nagraj Mani, Arbutus Biopharma Inc., USA

 12:10

Predicting Susceptibility and Resistance for Hepatitis B Virus Capsid Assembly Effectors
Bryan Cox, Emory University, USA

12:20Lunch
 
NASH AND HEPATOCELLULAR CARCINOMA
Chairs: Veronica Miller; Forum for Collaborative HIV Research, USA - Manal El-Sayed; Ain Shams University, Egypt
 15:30Plenary Presentation
NASH Globally: Pathways to Combination Therapy, Biomarkers and Outcomes
Arun Sanyal
Virginia Commonwealth University, USA
 16:10The Re-vival of Bile Acid Based Therapeutics for Children and Adults
Saul Karpen
Emory University, USA
 16:30Evolving Role of Real-World Evidence in NASH and HCC: From Bench to Poolside
Michael Fried
University of North Carolina at Chapel Hill, USA
 

ORAL ABSTRACT SESSION V
Chairs:
Robert Gish, Hepatitis B Foundation, USA - Mario Stevenson, University of Miami, USA

 16:50

Sustained SVR 2 years after HCV treatment with simeprevir, daclatasvir and sofosbuvir in patients with portal hypertension or decompensated liver disease
Eric Lawitz; Texas Liver Institute, USA

 17:00

High Efficacy and Safety of the combination HCV Regimen Grazoprevir and Elbasvir for 8 Weeks in Treatment-Naive, non-severe fibrosis HCV GT1b-Infected Patients: Interim Results of the STREAGER study
Brigitte Chanteranne; CHU Estaing, France

17:10Break
 
ELIMINATION, PREVENTION AND VACCINE Chairs: Frank Chisari, The Scripps Research Institute, USA - Michael Manns, Hannover Medical School, Germany
 17:30Plenary Presentation
Are we Getting Closer to an HCV Vaccine? 
Andrea Cox
Johns Hopkins University, USA
 18:00

Lessons learned towards a Vaccine and Functional Cure for HIV
Mario Stevenson
University of Miami, USA

 
ORAL ABSTRACT SESSION VI
 18:20

Hepatitis B virus splice variants are associated with and predictive of liver cancer (12)
Peter Revill, Victorian Infectious Diseases Reference Laboratory, Australia

 18:30

Seroclearance of HBsAg in Chronic Hepatitis B Virus Patients on Lamivudine, Tenofovir or Entecavir Therapy: A 10 Year Experience.
Suzane K. Ono Nita, University of Saõ Paulo, Brazil

 
18:40Adjourn to Closing Dinner
 

THURSDAY, DECEMBER 7, 2017

ADVANCES IN CLINICAL DEVELOPMENTS:
Chairs: Henry Masur; NIH, USA - Saul Karpen; Emory University, USA
 8:00Plenary Presentation
The Effectiveness of Treatment for Chronic Hepatitis C (and Hepatitis B) in Pediatric Populations

Manal H. El-Sayed
Ain Shams University, Egypt
 8:40Liver Directed Acetyl CoA Carboxylase Inhibitor GS-0976 For NASH
Adrian Ray
Gilead Sciences, USA
 9:00

Aramchol for NASH and beyond: From Scientific Rationale to Clinical Development. 
Carol Brosgart
University of California, San Francisco, USA

 9:20Regulatory Landscape for NASH
Veronica Miller
Forum for Collaborative HIV Research, USA
 9:40Immunotherapies and treatments for HCC
 
10:00Break
 
ORAL ABSTRACT SESSION VII Chairs: Jason Grebely, The University of New South Wales, Australia - Shyamasundaran Kottilil, University of Maryland, USA
 10:30

RNA Interference Screen Identified Farnesoid X Receptor (FXR) as a Host Dependency Factor for HBV Establishment in Primary Human Hepatocytes
Sumantra Ghosh; Gilead Sciences Inc, USA

 10:40

Evidence Supporting Liver Targeting of Tenofovir Exalidex (TXL)
Robert Foster; ContraVir Pharmaceuticals Inc., USA

 10:50

Two Doses of HEPLISAV-B™, a Hepatitis B Vaccine with a TLR9 Adjuvant, Compared with Three Doses of Alum-Adjuvanted ENGERIX-B® in Adults Aged 18 -70 Years
Randall Hyer; Dynavax, USA

 11:00

An Integrated Multidisciplinary Approach for Prediction of Fibrosis Progression and HCC Development in Chronic Hepatitis C Infected Patients Utilizing Genomics, Elastography, Imaging and Circulating Tumor Cells
Emmanuel Thomas; University of Miami, USA

 11:10

Delayed viral suppression during antiviral therapy increases hepatocellular carcinoma in HBeAg-positive chronic hepatitis B
Yoon Jun Kim, Seoul National University Hospital, South Korea

 11:20

Establishment of Functional Control and Normalization of Liver Function in HBeAg Negative Chronic HBV infection Following Combined Therapy with REP 2139 or REP 2165, Tenofovir Disoproxil Fumarate and Pegylated Interferon α-2a.
Andrew Vaillant; Replicor Inc., Canada

 11:30

Validation of a novel Transient Elastography for the Measurement of liver fibrosis
Jing Chen; Humanity and Health Research Centre, Hong Kong

 11:402018 & Beyond: Shifting the conversation
Eugene Schiff
University of Miami, USA
 12:10

Closing Remarks
Raymond F. Schinazi
Emory University, USA

 

Private: Program

An exciting program has been set up by the members of the Program Committee.
Program 9th HIV Pediatrics

 

 

 

 

 

 

 

Program

IVHEM 2017 will feature an exceptional program with invited lectures, round table discussions and interactive participation from delegates. The program is published below:

Subscribe to our newsletter to stay up-to-date on IVHEM 2017

 

Friday 17 November 2017

 13:00Welcome
By the workshop chairs
 13:05Setting the stage - Key challenges in elimination
Jordan Feld, MD, MPH | Biography
Research Director and Clinician-Scientist, Toronto Centre for Liver Disease, Toronto, Canada
 
  Session 1: Test and screening strategies
Chairs: Michael Ninburg & Maia Butshashvili
 13:20 WHO status report: Global response to the strategic framework;
Yvan Hutin, MD, PhD | Biography
 13:40Global response to the strategic framework; Technologies perspective
Francesco Marinucci, PhD | Biography
Head of HIV/HCV Unit, FIND, Geneva, Switzerland 
 14:00Real-life experiences - Egypt
Imam Waked, MD | Biography
Professor of Medicine, National Liver Institute, Shebeen El-Kom, Egypt
 14:10Real-life experiences - USA
A. Blythe Ryerson, MD, PhD | Biography
Lead Epidemiologist, Division of Cancer Prevention and Control, Atlanta, GA, USA
 14:20Discussion
 
 15:00Coffee break
 
  Session 2: Care & cure strategies
Chairs: Jordan Feld & Manal El-Sayed
 15:30Global trends in burden of disease
Graham Cooke, MD, PhD | Biography
Clinician scientist, Imperial College London, London, UK
 15:50How to measure your success; globally and locally
Yvan Hutin, MD, PhD | Biography 
 16:10Real-life experiences - bottlenecks & hurdles
  Moderators:
  Jordan Feld, MD, MPH | Biography
Research Director and Clinician-Scientist, Toronto Centre for Liver Disease, Toronto, Canada
  Manal El-Sayed, MD | Biography
Professor of Pediatrics, Ain Shams University, Cairo, Egypt
  Panel Members:
  Charles Boucher MD, PhD | Biography
Professor Virology, Erasmus Medical Center, Rotterdam, The Netherlands 
  Maria Cássia Jacintho Mendes Correa, MD |
Sao Paulo University-Medical School, Brazil
  Margaret Hellard, MBBS, FRACP, FAFPHM, PhD | Biography
Head Centre for Population Health, Burnet Institute, Melbourne, Australia
  Khin Pyone Kyi, MD, PhD | Biography
President of Board of Directors, Myanmar Liver Foundation
  Jeffrey Lazarus | Biography
Copenhagen University Hospital, Denmark
  Olufunmilayo Lesi, FF9WACP, FMCP | Biography
Professor & Head, Gastroenterology and Hepatology Unit, University of Lagos & Lagos University Teaching Hospital, Lagos, Nigeria
  Huma Qureshi, MD | Biography
Pakistan Medical Research Council, Islamabad, Pakistan 
  A. Blythe Ryerson MD, | Biography
Lead Epidemiologist, Division of Cancer Prevention and Control, Atlanta, GA, USA
 17:40Lessons learned - approaches to bottlenecks and hurdles
 
 18:00Networking and poster reception
 19:00 Workshop dinner
 

Saturday 18 November 2017

 7:30Early bird coffee
 Session 3: Prevention & screening strategies
Chairs: Olufunmilayo Lesi & Francesco Marinucci / Ryan Clary
  8:00Prevention transmission strategies on treatment - Pediatric population
Manal El-Sayed, MD | Biography
Professor of Pediatrics, Ain Shams University, Cairo, Egypt
  8:20Prevention transmission strategies prior to infection - People who inject drugs
Diana Sylvestre, MD | Biography
Executive Director, O.A.S.I.S. Clinic, Oakland, CA, USA
  8:40Prevention transmission strategies prior to infection - Incarceration
Lara Strick MD, MS | Biography
Infectious Disease Physician, Washington Department of Corrections, Turnwater, WA, USA & Clinical Assistant Professor, University of Washington, Seattle, WA, USA 
  9:00Prevention transmission strategies through strengthening the health system
Maia Butshashvili, MD, MS, PhD | Biography
Health Research Union (HRU)
  9:20Panel discussion
 
 10:00Coffee break
 
 Session 4: Innovative models to finance the health care problem
Chairs: Margaret Hellard & Charles Boucher
  10:30Poster Presentations
  11:30Medicines Patent Pool’s approach to scale up access to HIV and HCV treatment
Esteban Burrone
Head of Policy, Medicines Patent Pool, Switzerland
 12:00Micro-elimination as a strategy to reach global elimination
Jeffrey Lazarus| Biography
ISGlobal, Hospital Clínic, University of Barcelona
  12:30Closing Remarks
  12:45Lunch

 

Program

The Organizing Committee proudly presents the preliminary workshop program:

 

Wednesday 14 June 2017

16:00Workshop Opening
Angela Kashuba, PharmD and David Burger, PharmD, PhD
 
  Session 1: Approaches to Treating CMV and Influenza
  Chairs:
16:15 Current and Future Treatment of CMV
Robin Avery, MD - Johns Hopkins University, USA
16:45O_1: Single- and multiple-ascending doses (SAD/MAD) and food effect of orally administered JNJ-64155806 in healthy volunteers
Dr Thomas Kakuda
 
  Session 2: The Complexity of DDIs Involving PK Enhancement
  Chairs:
17:00O_2: Effects of cobicistat on tenofovir durability: is it time to rethink at TAF trials?
Dr Dario Cattaneo
17:15O_3: Pharmacokinetics of darunavir/cobicistat and etravirine alone and coadministered in HIV-infected patients
Dr Jose Molto
17:30O_4: Evaluation of the Drug-Drug Interaction Potential between Cobicistat-Boosted Protease Inhibitors and Statins
Dr Joseph Custodio
17:45O_5: Confirmation of the drug-drug interaction (DDI) potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives
Dr Sophia Majeed
18:00O_6: Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir
Dr Catia Marzolini
18:15Discussion
 
18:30End of Plenary Session - Poster Viewing (Posters 22 to 33) & Welcome Reception
 

Thursday 15 June 2017

 
  Session 3: Challenges and Approaches to Treatment in Special Patient Populations
  Chairs:
8:30 Current Challenges in Pediatric Drug Development 
Robert Ward, MD, FAAP, FCP - University of Utah, USA
9:00 Clinical Aspects of Pediatric Treatment
Tim Cressey, PhD - Chiang Mai University, Thailand
9:30O_7: A Comparison of the Pharmacokinetics of Dolutegravir during Pregnancy and Postpartum
Dr Pauline Bollen
9:45O_8: Relationship between dolutegravir plasma exposure, quality of sleep and its functional outcome in patients living with HIV over the age of 60 years.
Dr Marta Boffito
10:00Discussion
 
10:15Coffee break + Poster Viewing (Posters 34 to 50) + Group Picture
 
  Session 4: Hepatitis B Virus
  Chairs:
11:45 HBV therapy & Approaches to Cure
Jordan Feld, MD, MPH - Toronto Western Hospital Liver Center, Canada
12:15Discussion
 
  Session 5: Exploration of Less-drug Regimens
  Chairs:
12:30O_10: Pharmacokinetics of Dolutegravir and Rilpivirine after Switching to the Two-Drug Regimen from an Efavirenz- or Nevirapine-Based Antiretroviral Regimen: SWORD-1/2 Pooled PK Analysis
Dr Kimberly Adkison
12:45O_11: HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract.
Dr Sandrine Lefeuvre
 
13:00Lunch
 
  Session 6: Implications of Drug Transport and Metabolism in Drug Development
  Chairs:
14:15 Transporter mediated DDI
Kathy Giacomini, PhD - University of California, San Francisco, USA
14:45 FDA perspective
Kellie Reynolds, PharmD - U.S. Food & Drug Administration, USA
15:15O_12: Examining the Basis of Drug-Drug Interaction Labeling Recommendations for Antiviral Approvals from 1998 to 2015
Dr Tyler Shugg
15:30O_13: CYP3A induction data can predict other P450 and drug transporter DDI liability: An example of carbamazepine and rifabutin with sofosbuvir and P-gp
Dr. Brian Kirby 
15:45Discussion
 
16:00Coffee break
 
  Session 7: Clinical Cases
  Chairs:
Clinical Case Discussions
16:30 Challenges in managing the aging HIV-infected patient
Babafemi Taiwo, MBBS - Northwestern University, USA
17:00 DDI’s in Aging HIV infected Patients
Alice Pau, PharmD - National Institutes of Health, USA
17:30 DDI’s in Aging HCV infected Patients
Elise Smolders, MSc - Radboudumc Nijmegen, The Netherlands
 
18:00End of Plenary Session - Workshop Dinner
 

Friday 16 June 2017

 
  Session 8: Long Acting Antivirals: Advanced drug delivery
  Chairs:
8:30 Long Acting Antivirals: Advanced drug delivery
Mark Milad, PharmD - Bill & Melinda Gates Foundation, USA
9:00O_14: Pharmacokinetics of Co-encapsulated Truvada® with Ingestible Sensor to Assess Adherence
Dr Nathan Hanan
9:15O_15: Identification of long-acting NRTI candidates through in silico modelling
Dr Marco Siccardi
9:30O_16: A mathematical model that predicts virological failure and elucidates the impact of lymph node drug penetration
Dr Steven Sanche
9:45O_17: Early Safety, Tolerability, and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects
Dr Mark Johnson
10:00Discussion
 
10:15Coffee break + Poster Viewing (Posters 51 to 60)
 
  Session 9: Hepatitis C Virus
  Chairs:
11:00O_18: Drug-drug interactions of Glecaprevir and Pibrentasvir with Pravastatin, Rosuvastatin, or Dabigatran etexilate
Dr Matthew Kosloski
11:15O_19: Influences on Pharmacokinetics of ledipasvir, sofosbuvir and GS-331007 in patients with decompensated cirrhosis – results from the UK Expanded Access programme.
Dr Omar Elsherif
11:30O_20: Evaluation of Drug-Drug Interactions between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens
Dr. Kimberly Garrison
11:45O_21: The Potential Role of PK-Based Drug Interactions in FAERS-Reported Rhabdomyolysis Cases in Patients Receiving a DAA Regimen and a Statin
Dr Su-young Choi
Debate: Do we need more HCV Drugs?
12:00 Pro Standpoint
Nancy Reau, MD - Rush University Medical Center, USA
12:15 Con Standpoint
Jürgen Rockstroh, MD - University of Bonn, Germany
12:30Discussion
 
13:00Lunch
 
  Session 10: Challenges in Drug Development for Other Viruses Than HIV or Hepatitis
  Chairs:
14:00 Merck: CMV 
 Cyrus Badshah, MD, PhD  - Merck, USA
14:15 Janssen: Influenza
Thomas Kakuda, PharmD - Janssen/Alios, USA
14:30 Gilead: RSV
Polina German, PharmD - Gilead, USA
14:45Discussion
 
15:00Closure of the Workshop

The following invited speakers have confirmed their contribution to the workshop:

 

 

Program

The final agenda for the 1st Andean Pacific Workshop on HIV and Hepatitis is listed below. 

Download a PDF of the program here.

ANDEAN Pacific - Online program(1)

Friday 30 June - Day 1

8:15 - 9:15Symposium - Chilean AIDS Cohort
 
9:15Workshop opening 
Carlos Beltrán, MD
 
  Session 1: Challenges for HIV care in Latin America
9:30HIV in Latin America: 35 years later
Marcelo Wolff, MD , FACP, FIDSA
Universidad de Chile, Santiago, Chile
10:00WHO Target 90-90-90 : Achievable for Latin America
Alejandro Afani, MD, FACP
Universidad de Chile, Santiago, Chile
10:30Difficult to reach populations in Latin America
Ana Paulina Celi, MD
Asociación Panamericana de Infectología, Quito,
Equador
11:00Discussion
 
11:15Coffee Break
  
  Session 2: Prevention of transmission
11:45New approaches for preventing transmission
Charles Boucher, MD, PhD
Erasmus Medical Center, Rotterdam, The Netherlands
12:15State-of-the-art lecture on PrEP
Mauro Schechter, MD, PhD
Federal University of Rio de Janeiro, Rio de Janeiro, Brasil
12:45Discussion
 
13:00Lunch
 
  Session 3: Clinical strategies
14:00Clinical Implications of low level viremia/failure and resistance
Francesca Ceccherini, MD
University of Rome Tor Vergata, Rome, Italy
14:30Abstract driven presentations
15:30Discussion
  
15:45Coffee break
 
  Session 4: Diagnostic tools
16:15Early Diagnosis & Testing
Susana Cabrera, MD
Universidad de la República, Montevideo, Uruguay
16:45Abstract-driven presentations
17:30Discussion
 
18:00- 19:00Symposium - MSD
 

Saturday 1 July - Day 2

 
  Session 5: Viral Hepatitis in Latin America
9:00Local situation in LA (epidemiology / treatment options)
Jorge Contreras, MD
Clínica Alemana - Universidad del Desarrollo Chile, Santiago, Chile
9:30Implementation of DAAs in clinical management
Mark Nelson, MD, PhD
Chelsea and Westminter Hospital, London, UK
10:00Strategies for Hepatitis C Elimination
Francesca Ceccherini, PhD
University of Rome Tor Vergata, Rome, Italy
10:30Discussion
10:45Poster viewing & Coffee break
 
13:00Lunch
 
  Session 6: Special Populations
14:00HIV- Hepatitis co-infected patients
Pedro Cahn, MD, PhD
Fundación Huésped, Buenos Aires, Argentina
14:30HIV in Woment - pregnancy
Isabel Cassetti, MD
Fundación Helios Salud, Buenos Aires, Argentina
15:00The aging HIV infected patient - neurological issues - poly pharmacy
Ernesto Martinez Buitrago, MD
Universidad del Valle, Cali, Colombia
15:30Discussion
 
16:00Coffee Break
 
  Session 7: ARV therapy: present and future
16:30Do we really need new drugs?
Mark Nelson, MD, PhD
Chelsea and Westminer Hospital, London, UK
16:50Present and future of ART in Latin America
Carlos Beltrán, MD
Chilean AIDS Cohort (ChiAC), Santiago, Chile
17:10HIV cure and eradication
Ricardo Diaz, MD, PhD
NIFESP Laboratorio de Retrovirologia, São Paulo, Brasil
 
17:30Panel discussion: Strategies for simplication
 
18:00Closure of the workshop

 

Program

INTERACTIVE PROGRAM

An exciting and interactive program is currently being established. You will have ample chance to meet the experts and discuss cases in smaller break-out groups. You can also look forward to invited lectures, oral abstract presentations, poster presentations and discussions. Join us and learn about the various approaches and treatments in Europe and take part in shaping innovative healthcare for the future.

​Download the preliminary program agenda (version: June 2017).

Program

Saturday, 1 October

 

Program

Final program is now available!

To download the program, please follow this link:  7th HIV & Aging_PROGRAM

 

Invited speakers:

 

 

 

 

 

 

 

 

 
 

Program

View the IVHEM 2016 program below:

Friday 2 December

13.00hOpening of the workshop
by the Workshop Chairs
13.15hOpening lecture on WHO programs
Gottfried Hirnschall

Head, HIV/Viral Hepatitis Department
World Health Organization, USA
 
  Session 1: Results of National programs: Barriers & Successes
13.45hNational perspectives in Europe - common themes and challenges
Angelos Hatzakis
Professor of Epidemiology and Preventive Medicine
Athens University Medical School, Athens Greece
Co-Chair, Hepatitis B and C Public Policy Association
14.15hNational Programs - the Netherlands
Anouk Urbanus

‎Policy Advisor Infectious Diseases
National Institute of Public Health and the Environment, Bilthoven, the Netherlands
14.30hNational Programs - Egypt
Wahid Doss 
Professor, Cairo University, Cairo, Egypt
Head, National Committee for Control of Viral Hepatitis, Egypt
 14.45hNational Programs - Australia
Margaret Hellard
Head, Centre for Population Health
Burnet Institute, Melbourne, Australia
15.00hNational Programs - US
John Ward
Director, Viral Hepatitis Program
Centers of Disease Control and Prevention, Atlanta, USA
15.15hDiscussion
 
15.45hGroup Picture
 
16.00hCoffee Break
 
  Session 2: Progress towards elimination - Specific Populations
16.30hProgress towards elimination in the Australian prison sector
Andrew Lloyd 
Infectious Diseases Physician & Prisoner Health Researcher
Kirby Institute, University of New South Wales, and Justice Health & Forensic Mental Health Network, Sydney, Australia
16.50hChildren & Pregnant women
Manal El-Sayed
Professor of Pediatrics
Ain Shams University, Cairo, Egypt
17.10hPeople who inject drugs
Olav Dalgard
Professor of Infectious Diseases
Akershus University Hospital, Lørenskog, Norway
17.30hDiscussion
 
18.00hEnd of Day 1
A Networking reception and Workshop dinner are organized after the last session.
 

Saturday 3 December

  Session 3: Diagnosing
08.30hWHO Guidelines and Policies of testing
Margaret Hellard
Head, Centre for Population Health
Burnet Institute, Melbourne, Australia
08.50hProgess in testing technologies
Dmytro Donchuk
Infectious Diseases Specialist, HIV, TB and Viral Hepatitis Adviser
Médecins Sans Frontières, Brussels, Belgium
09.10hChallenges in Monitoring (POC)
Isabelle Andrieux-Meyer
HIV/HCV Team Lead
Drugs for Neglected Diseases initiative, Frontières, Geneva, Switzerland
09.30hChallenges in regards to resistance
Mark Nelson
Consultant Physician
Chelsea and Westminster Hospital, London, United Kingdom
09.50hDiscussion
 
10.00hCoffee Break
 
  Session 4: Reducing Transmission and harm
10.30hGlobal Injection Safety Campaign and Prevention Strategies
Arshad Altaf 

Consultant Injection Safety
World Health Organization, Geneva, Switzerland
10.50hCan we afford not to treat reinfection 
Peter Vickerman
Professor of Infectious Disease Modelling
University of Bristol, Bristol, United Kingdom
11.10hCreating awareness and sharing the knowledge
Anya Sarang
Director
Andrey Rylkov Foundation for Health and Social Justice, Moscow, Russia
11.30hCommunity and harm reduction response to infection and reinfection
Eberhard Schatz
Coordinator European Initiative on Hepatitis C and Drug Use
Correlation Network c/o Foundation De Regenboog Groep, Amsterdam, the Netherlands
11.50hDiscussion
 
12.15hLunch
 
  Session 5: Future scenarios for elimination
13.15hVaccine development and results
Andrea Cox 
Professor of Medicine
Johns Hopkins School of Medicine Baltimore, MD, USA
13.35hMinimising treatment duration and doses
Jordan Feld
Research Director and Clinician-Scientist
Toronto Centre for Liver Disease, Toronto, Canada
13.55hRole of generic drugs
Andrew Hill
Senior Visiting Research Fellow
Liverpool University, Liverpool, UK
14.15hFinancial models for high- and low income countries
Pieter Walhof
Director PharmAccess and Health Insurance Fund
PharmAccess Foundation, Amsterdam, the Netherlands

14.35hBuilding global capacity
Stefano Vella
Chair of Global Health
Istituto Superiore di Sanità
 
14.55hRound table Discussion
 
15.30hProgram adjournment

 

Program

A comprehensive program has been set up  with the following topics: 
• Unmet needs and challenges of the current alternative of treatment
• Optimization of the management of HIV
• Management of resistance in resource-limited settings
• Management of co-morbidities and co-infection
• Pediatric and Adolescent HIV Care
• The future in HIV care

The presentations of the courses can be found here

For speakers, please go to the "Faculty" page.

The country specific programs can be downloaded here.

Final Agenda_South Africa

FINAL Agenda_Botswana

FINAL Agenda_Kenya

Final Agenda_Namibia

Objectives:
After following this course, the participant will:
• Have an updated knowledge on the current treatment strategies
• Have insight in the management of co-morbidities
• Be able to recognize resistance characteristics of antiretroviral drugs
• Be able to identify potential drug-drug interactions

 

Program

ACHA 2018 program consists of HIV, Hepatology, HBV, HCV, Co-infections and Public Health session. Please click on here to download the PDF version of the program or the image below to view the agenda online. The information is subject to change.

Program_ACHA2018

 

Program

  

 

Day 1 - Saturday, 25 May 2019

 
 9:00 AMThe opening of the workshop 
 Session 1: HIV/AIDS in China
Chairs: Yongtao Sun, Wei Lyu
 9:15 AMStudy on HIV variation and evolution and its impact on molecular epidemiology and drug resistance surveillance
Yiming Shao, MD, PhD
China CDC
 
 

9:40 AM

Guidelines for diagnosis and treatment of HIV/AIDS in China (2018)
Taisheng Li, MD, PhD
Peking Union Medical College Hospital, China
 
 10:05 AMCoffee break 
 Session 2: Prevention of HIV-infection
Chairs: Hao Wu, Yaokai Chen
 10:35 AMHIV Pre-Exposure Prophylaxis (PrEP)
Roy Gulick, MD, MPH
Weill Medical College of Cornell University, USA
 
 11:00 AMPrEP uptake preferences among men who have sex with men in
China: results from a National Internet Survey
Fujie Zhang, MD, PhD 
Beijing Ditan Hospital, Capital Medical University, China
 11:25 AMDiscussion 
 11:40 AMGroup photo 
 11:50 AMLunch 
 12:50 PM Satellite symposium
A new HIV treatment Era: F/TAF backbone
 Session 3: 
Antiviral Therapy & Cure
Chairs: Weiping Cai, Biao Zhu
 1:50 PMHIV Drug Resistance 
Charles Boucher, MD, PhD
Erasmus Medical Center, Erasmus University, the Netherlands
 
 2:15 PMNovel treatment strategies - two versus three drugs
Jonathan Schapiro, MD
Sheba Medical Center, Israel
 
 2:40 PMProgress review on HIV Cure
Bonaventura Clotet, MD, PhD
Hospital Universitari " Germans Trias I Pujol", Spain
 
 3:05 PMDiscussion 
 3:20 PMCoffee break / Poster viewing 
 Session 4: 
Clinical management of HIV coinfections
Chairs: Yun He, Hongxia Wei
 3:50 PMHIV/TB co-infection in China
Hongzhou Lu, MD, PhD
Shanghai Public Health Clinical Center, Fudan University, China
 
 4:15 PMClinical characteristics and prognostic factors of cryptococcal meningitis among HIV-infected  patients
Yinzhong Shen, MD
Shanghai Public Health Clinical Center, Fudan University, China
 
 4:40 PM

Clinical management of HIV-HBV and HIV-HCV coinfection 
Jürgen Rockstroh, MD, PhD

University of Bonn, Germany

 
 5:05 PMDiscussion 
 5:20 PMEnd of Day 1 
 

Day 2 - Sunday, 26 May 2019

 
 Session 5: 
Progress in HBV treatment
Chairs: Hui Zhuang, Hui Wang
 9:00 AMProgress on HBV treatment
Jinlin Hou, MD 
Nanfang Hospital, Southern Medical University, China
 
 9:25 AM

HBV-infection in immune comprised people
Wenhong Zhang, MD, PhD 
Huashan Hospital, Fudan University, China

 
 

9:50 AM

 

Novel biomarkers for chronic hepatitis B
Xiaonan Zhang, PhD
Shanghai Public Health Clinical Center, China
 
 10:15 AMDiscussion 
 10:30 AMCoffee break 
 11:00 AM

Update of Chronic hepatitis B with fatty liver
Jiangao Fan, MD, PhD
Xinhua Hospital Affiliated to Shanghai Jiaotong University, China

 
 11:25 AM

Acute on chronic liver failure ( TBC)
Yumin Xu, MD, PhD
Ruijin Hospital Affiliated to Shanghai Jiaotong University, China

 
 11:50 AMDiscussion 
 12:00 AMLunch 
 1:00 PM 
Satellite Symposium:
Adaptable Best Practice Service Models for HIV & Viral Hepatitis
  Scott McGill
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine
Australia
 
  Special talk supported by Becton Dickinson 
  2:00 PMThe advanced technology of MDR-TB diagnosis
Xin Shen
Shanghai CDC, China
 
 Session 6: 
Progress in HCV Treatment
Chair: Lingyun Shao
 2:25 PMHCV epidemiology
Lai Wei, MD
Peking University People's Hospital, China
 
 2:50 PMHepatitis C therapy: Unique issues and Challenges in Asia
Pei-Jer Chen, MD, PhD
Nation Taiwan University College of Medicine Institute of Molecular Medicine
 3:15 PMThe superinfection of hepatitis E virus in chronic hepatitis patients
Jun Zhang, PhD
School of Public Health, Xiamen University,China
 
 3:40 AMDiscussion 
 3:50 AMCoffee break 
 Session 7: 
Progress in viral hepatitis Cure/Elimination
Chair: Liang Chen
 4:20 PM Progress HBV cure research
Jidong Jia, MD, PhD
Beijing Friendship Hospital, Capital Medical University, China
 
 4:45 PMProgress HCV cure / HCV elimination
Jürgen Rockstroh, MD, PhD
University of Bonn, Germany
 
 5:10 PMDiscussion 
 5:20 PMClosing remark
Wenhong Zhang, MD, PhD
Xinhua Hospital Affiliated to Shanghai Jiaotong University, China
 
 5:35 PMEnd of Day 2 

 *Simultaneous interpretation will be offered throughout the meeting.

Program

Program

  • Please download your copy of the APACC 2016 program here.
  • Satellite symposia information can be found here.

Confirmed speakers

 

Program

We are proud to announce that the program has been set. For a full overview of the program, please click here.

The following speakers have confirmed their participation:

 

Program

The Organizing Committee proudly presents the workshop program: Program HBVCure Workshop 2016.

 Wednesday 9 November 2016

  Session 1
  Chairs: Fabien Zoulim and Scott Fung

08.45 AMLampertico, Pietro 2013Current Status of HBV Therapy
Pietro Lampertico, MD, PhD
University of Milan, Italy University of Milan, Italy
09.05 AMJanssen, Harry 2013Why do we need new treatments and what is our definition of cure?
Harry Janssen, MD, PhD
Toronto Centre for Liver Disease, Canada
09.25 AMDiscussion
 
09.45 AMCoffee break & Group Picture
 
  Session 2
  Chairs: Stephen Locarnini and Charles Boucher
10.30 AMNew Treatment Options: Virological Approach
 - Entry inhibition
Urban, Stephen, 2016 120x160Stephan Urban, PhD
Heidelberg University, Germany
 - CCC – DNA inhibition
Levrero, Massimo 2016 120Massimo Levrero, MD
University La Sapienza, Rome, Italy
 - Small interfering RNA’s
Locarnini, Stephen 2015_120x160Stephen Locarnini, BSc, PhD, MBBS, FRC
Victorian Infectious Diseases Reference Laboratory Melbourne, Australia
 - New Nucleoside Analogue & Capsid inhibition
Zoulim, Fabien 2011_120Fabien Zoulim, MD, PhD
INSERM, Villejuif, France
 - Assembly and Secretion Inhibitors
©Allure West Studios.Tim Block, PhD
Hepatitis B Foundation, Doylestown, USA
 
  Session 3
  Chairs: Mala Maini and Jordan Feld
01.30 PMHow does HBV interact with the immune system?
Thimme, Robert 2016Robert Thimme, MD
University of Freiburg, Germany
01.55 PMNew Treatment options: Immunomodulatory Agents
 - Therapeutic Vaccines 
Chang, Khyong-Mi 120x160Kyong-Mi Chang, MD
University of Pennsylvania, Philadelphia, USA
 - Adaptive Immunity: - PDL Blockers
Maini, Mala 2016Mala Maini, Prof.
University College London, UK
 - Innate Immunity
Gehring, Adam 2014Adam Gehring, PhD
Toronto Centre for Liver Disease, Canada
02.40 PMDiscussion
 
0300 PMCoffee break
 
  Session 4
  Chairs: Harry Janssen and Stephan Urban
03.30 PMHow to combine new treatments? Scientific approach
Jordan Feld, MD
Toronto Centre for Liver Disease, Canada
03.50 PMHow to combine new treatments? Clinical approach
Marion Peters, MD
University of California, San Francisco, USA
04.10 PMDiscussion
 
04.30 PMRoundtable discussion "trial design, treatment endpoints and regulatory approach”.
 
05.30 PMClosure and adjournment, followed by a workshop dinner

 

Private: Program

Downloadable:

3rd CEE CEE Meeting on Viral Hepatitis and Co-infection with HIV_Program

Wednesday 27 September - Day 1

8:30 Registration and breakfast
9:00 Opening of the Meeting
Session 1: Epidemiology / access to treatment
9:10 

Local situation in in Slovenia and Balkan Countries
Mojca Maticic, MD, PhDUniversity Medical Centre Ljubljana, Slovenia

9:20

Local situation in Ukraine
Olga Golubovska, MD - Bogomolets National medical University, Ukraine

9:30 Local situation in Russia
Vadim Rassokhin, MD  - First St. Petersburg State Medical University named Acad IP Pavlov, Russia
9:40 Local situation in Romania
Oana Sandulescu, MD, PhD - Carol Davila University of Medicine and Pharmacy, Romania
9:50 Local situation in Baltic Countries
Saulius Caplinskas, MD, PhD - Lithuanian Centre for Communicable Diseases and AIDS, Lithuania
10:00 Local situation in Georgia
Akaki Abutidze, MD, MPH - AIDS and Clinical Immunology Research Centre, Georgia
10:10Local situation in Czech and Slovak Republics
Viktor Aster, MD, PhD - Charles University, Czech Republic
10:20 Local situation in Turkey
Cihan Yurdaydin, MD, PhD - University of Ankara, Turkey
10:30Local situation in Poland
Andrzej Horban, MD, PhD - University of Warsaw, Poland
10:40 Local situation in Hungary
Béla Hunyady, MD - Somogy County Kaposi Mór Teaching Hospital, Hungary
10:50 Coffee Break
11:15 Hep-CORE study: management of HBV and HCV infections throughout Europe
Jeffrey Lazarus, PhD - Copenhagen University Hospital, Denmark
11:40 New testing strategies for HCV: how can we achieve the WHO targets?
Mario Poljak, MD, PhD - University of Ljubljana, Slovenia
12:05 

Round table discussion: access to HepC treatment

Introduction to Access to hepC treatment in EECA
Liudmyla Maistat - Medicines Patent Pool, Switzerland

Key barriers to hepC treatment for PWIDs
Eberhard Schatz - Corellation Network, the Netherlands

Direct price negotiations
Natalia Kravchenko - Alliance for Public Health, Ukraine

Compulsory licensing and patent opposition
Sergey Golovin - Treatment Preparedness Coalition, Russia

MPP progress in VL
Liudmyla Maistat - Medicines Patent Pool, Switzerland

13:00Group picture
13:15Lunch break
14:00Industry-sponsored symposium
Session 2: Challenges in the management of HCV infected patients
15:00 Management of HCC in HCV -infected patients
Markus Peck-Radosavljevic, MD - Klinikum Klagenfurt am Wörthersee, Austria
15:30Clinical case: re-treatment of HCV DAA failure with 3-class resistance
Pavel Khaykin, MD - MainFachArzt, Germany
15:50 Discussion
16:00 Coffee break
Session 3: Epidemiology, clinical presentation and management of Hepatitis E virus
16:30Management of Hepatitis E virus
Heiner Wedemeyer, MD - Medical School Hannover, Germany
17:00Discussion
17:15Industry-sponsored symposium
18:15Welcome reception and poster viewing
19:00Networking dinner - pre-registration required

Thursday 28 September - Day 2

8:30 Industry-sponsored symposium
Session 4: Treatment challenges in HIV & HCV – special populations
9:30 

Special challenges in curbing the HIV epidemic in Central/Eastern Europe
Miłosz Parczewski, MD, PhD - Pomeranian Medical University, Szczecin, Poland

Abstract - driven presentations:

10:00 Results of Hepatitis C virus (hcv) treatment program among people with hiv/hcv co-infection who inject drugs (PWID)
Mr. Sergii Filipovich
#1
10:10 HIV infection outbreak among IDUs in Minsk
Prof. Vladimir Eremin
#8
10:20 

Discussion

10:30Coffee break
Session 5: Abstract - driven presentations
11:00Real-world effectiveness of ledipasvir/sofosbuvir in hepatitis C virus genotype 1, 2 and 3 infection: single-center experience within Georgian hepatitis C elimination program
Prof. Tengiz Tsertsvadze
#2
11:10 Clinical characteristics of patients seeking care for chronic HCV infection – results from the large observational study in Central and Eastern European region and Kazakhstan (MOSAIC Study)
Dr. Béla Hunyady
#3
11:20Changes in demographic, epidemiological and virological characteristics of patients with chronic hepatitis B virus infection in Slovenia between 1997 and 2010
Dr. Nina Kmet Lunarcek
#4
11:30 Prognostic factors for liver fibrosis regression following sustained virologic response in patients with hepatitis C treated with direct acting antivirals
Dr. Oana Sandulescu
#5
11:40 Direct-acting antivirals Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir with or without Ribavirin in HCV genotype 1-infected treatment-naïve or treatment-experienced patients with or without cirrhosis: real-life experience in Lithuania and Latvia
Dr. Ligita Jancoriene
#6
11:50 Discussion
Special session: Future directions of ARVs
12:00Virologist Perspective
Charles Boucher, MD, PhD - Erasmus University, the Netherlands
12:15Clinician Perspective
Jonathan Schapiro, MD - Sheba Medical Centre, Israel
12:30Pharmacologist Perspective
Saye Khoo, MD, PhD - University of Liverpool, United Kingdom
12:45

Discussion

13:00Lunch break
Session 6 Future in Diagnostic & Therapeutic Approaches
13:45

Innovative diagnostics for HIV, HBV and HCV
Dan Otelea, MD, PhD - Nat. Institute for Inf. Diseases “Prof. Dr. Matei Bals”, Romania

14:15The challenges in hepatitis B vaccination
Pierre Van Damme, MD, PhD - University of Antwerpen, Belgium
14:45Discussion
15:00Closing remarks

 

INVITED SPEAKERS

 

Draft program

  
10.00 AMRegistration & Coffee
10.30 AMOpening of the workshop
  
Topic 1:
Current Management of the Patient with Hepatitis C
10.45 AMIs Resistance testing in 2017 still relevant
11.15 AMDiscussion
  
Topic 2:
Use of HCV positive donors
11.30 AMThe US perspective (15 min.)
 The European perspective (15 min.)
 The Asian perspective (15 min.)
 Panel Discussion ( 30 - 45 min.)
  
1.00 PMLunch
  
Topic 3:
Management guidance for Chronic Hep B and Hep E
2.00 PMPost transplant management: Do we need guidelines for HBV
2.30 PMDiscussion
2.45 PMClinical case discussions
 Hepatitis E patient
  
  
3.30 PMCoffee Break
  
Topic 4:
BMI 50 - Next Frontier in Transplantation
4.00 PMUK policy: stop smoking and lose weight
4.20 PMBariatric procedures for NASH in the setting of Transplantation - Endoscopic procedures
4.40 PMBariatric procedures for NASH in the setting of Transplantation - Surgery
5.00 PMDiscussion
  
5.30 PMClosure

Program

The 12th International workshop on HIV Transmission meeting aims to enhance the integration of all relevant disciplines to constrain the spread of (drug-resistant) HIV and to provide a forum to discuss the various aspects of the transmission of HIV. The meeting's distinctive format will create a lively dialogue amongst panelists, engage attendees in discussions, and identify the best ways to move research forward.

Below the preliminary program for the International workshop on HIV Transmission is published. Please note that this program is subject to change.

Download program as PDF (version 13 July 2017):

Program Transmission

Discussion

Discussion

Friday 21 July

 
10.00 - 11.00 hRegistration
 
11.00 h

Opening
Christiane Moog & Eric Hunter

 
  Session 1: Prevention strategies
  Chairs: Christiane Moog & Eric Hunter

11.30 h Invited lecture: Vaccine induced susceptibility vs protection
Roger LeGrand
Comissariat à l'Energie Atomique, Fontenay-aux Roses, France
  Abstract-driven presentations
12.00 - 12.15 hIdentification of rapid and emerging transmission clusters from genetic network
Tsz Ho Kwa
Jockey Club School Of Public Health And Primary Care, The Chinese University Of Hong Kong, Hong Kong
12.15 - 12.30 hPhylogenetic, epidemiological and virological insights on the rise of large cluster outbreaks fueling the HIV-1 epidemic among Men having sex with Men within Quebec
Bluma Brenner
Lady Davis Institute, Canada
12.30 - 12.45 hA novel NRTI, EFdA, effectively penetrates and suppresses HIV infection in all individual compartments of male genital tract
Martina Kovarova
University Of North Carolina At Chapel Hill, USA
12.45 h Discussion & evaluation forms
 
13.15 hLunch break
 
  Session 2: Blocking HIV Transmission
  Chairs: Gabriella Scarlatti & Stacy Carrington Lawrence

14.15 h Invited lecture: Passive antibody to block transmission
Mike Cohen, MD
UNC Centers for AIDS Research, The University of North Carolina at Chapel Hill, Chapel Hill, USA
  Abstract-driven presentations
14.45 h A Combination of Broadly Neutralizing Antibodies Prevents In Vitro SHIV162P3 Cell-Free Transmission More Efficiently Than Cell-to-Cell Transmission
Karunasinee Suphaphiphat
CEA, France
15.00 h Broadly neutralizing antibody against HIV-1 Env blocks infection of the first cell after mucosal challenge of macaques
Christiane Stahl-Hennig
Deutsches Primatenzentrum GmbH, Germany
15.15 h Non-neutralizing Antibodies Targeting HIV’s V1V2 Domain Exhibit Strong Inhibitory Activities
Luzia Mayr
Inserm U1109, France
15.30 h Discussion & evaluation form
 
16.00 hCoffee Break
 
  Session 3: Round table discussion: Making PrEP a succes
  Chairs: Tom Hope & Gina Brown

16.30 h Invited lecture: Behaviour perspective
Ian McGowan, MD, PhD, FRCP
University of Pittsburgh, Pittsburgh, USA
17.00 h Invited lecture: Clinical perspective 
Annemarie Wensing, MD, PhD
University Medical Center Utrecht, the Netherlands
  Abstract-driven presentation
17.30 h New formulation of injectable and removable long-acting dolutegravir is effective in prevention of HIV transmission with high dose vaginal HIV challenges
Martina Kovarova
University Of North Carolina At Chapel Hill, USA
17.45 h Round table discussion
 
  Guided Poster Tour
  Chairs: Gina Brown & Eric Hunter

18.15 h Evaluating the feasibility of implementing UNAIDS' 90 90 90 strategy, achieving universal access to treatment, and eliminating HIV in Malawi
Laurence Palk
University Of California, Los Angeles, USA 
18.15 h OLA-Simple 1.0: Laboratory Kit for HIV Drug Resistance Testing in Low-Resource Settings
Nuttada Panpradist 
University Of Washington, USA
18.15 hCouples HIV Testing and Counseling for Heterosexual Pregnant Women and their Partners Seeking Prenatal Care in Philadelphia, PA
Itoro Inoyo
Drexel University College of Medicine, Division of Infectious Diseases & HIV Medicine, USA
18.15 h An HIV Risk Assessment Tool to Predict HIV Transmission within HIV Serodiscordant Couples
Kristin Wall
Emory University, USA
19.30 hNetwork dinner
 

Saturday 22 July

 
   Session 4: Early events of HIV Transmission
   Chairs: Walid Heneine & Jean Patterson

08.30 h Invited lecture: Trafficking of HIV out of the mucosa
Claudia Cicala, PhD
NIAID, Bethesda, USA
  Abstract-driven presentations
09.00 h Defining the first phases of penetration and infection of HIV/SIV into the mucosal tissues
Camille Ducloy
Inserm UMR 1109, France
09.15 hIntestinal Dendritic Cells and Macrophages Play a Different Role in the Early Events of HIV-1 Transmission.
Mariangela Cavarelli
Cea, France
09.30 hThe impact of specific N-linked glycosylation patterns on HIV-1 transmission fitness
Katja Klein
University Of Western Ontario, Canada
09.45 hDiscussion & evaluation form
 
10.00 hCoffee break & Poster Viewing
 
  Session 5:  Post Transmission Events
  Chairs: Eric Arts & Phylis Kanki

  Abstract-driven presentations
10.30 hGut Dysbiosis During Acute HIV Infection
Angela Wahl
University Of North Carolina At Chapel Hill,USA
10.45 hHIV-1 Vif adaptation to host immune pressure impact of cytidine deaminases and host HLA.
Nicole Reddy
Africa Health Research Institute , South Africa
11.00 hDeep sequencing reveals viral evolution in Gag within protective HLA alleles B*57:02, B*58:01 and B*7 supertype individuals acutely infected with HIV-1 subtype C in Durban, South Africa
Kamini Gounder 
Hiv Pathogenesis Programme, University Of Kwa-zulu Natal, South Africa
11.15 hUnexpected antibody isotypes and neutralizing profile in patients controlling HIV
Jéromine Klingler
Inserm Umr_s 1109, Francexx
11.30 hTransmitted drug-resistance in newly diagnosed HIV drug-naïve individuals in Portugal
Marta Sofia Pingarilho
Ihmt, Portugal
11.45 hDiscussion & evaluation form
 
12.00 hLunch
 
  Session 6: Round table discussion: Using transmission networks for targeted interventions
  Chairs: Anne Wensing & Jan Albert

13.00 h Introduction: Using transmission networks for targeted interventions
Charles Boucher, MD, PhD
Erasmus Medical Centre, Rotterdam, The Netherlands
13.15 h Round table discussion
Faculty
 
14.00 hClosure of the Workshop

 

Program

  • Please find below the latest version of the program agenda, including accepted oral and poster presentations. You can also download a copy of the program HERE.
  • Missed the 2nd edition? You can view the presentations and the videos on the Infectious Diseases Online.

Agenda

Last updated: 2017-10-06

Thursday, October 19, 2017

Key note
Chair: Alan Landay 
09:30hBrain-Gut-Microbiota interactions and intestinal health
Wendy Henderson, NINR, NIH, DHHS
 
Session 1: Pathogenesis
Chairs: Cara Wilson & Stacy Carrington-Lawrence
10:30hMining adaptive immunity to identify disease-promoting microbiota members in HIV
Ivan Vujkovic-Cvijin, National Institutes of Health, Mucosal Immunology Section, USA
11:00hMicrobial colonization of the gut and brain development in infancy
Rebecca Knickmeyer, UNC School of Medicine, UNC-Chapel Hill, USA
11:30hDifferential responses of colonic ILCs to gut commensal bacteria altered during HIV infection (Abstract #: O_01)
Moriah Castleman, USA
11:45hMicrobial dysbiosis does not alter immune activation or disease progression in SIV-infected rhesus macaques (Abstract #: O_02)
Alexandra Ortiz, USA
12:00hDiscussion & Session Evaluation
 
12:15hGroup Photo & Lunch Break
 
Session 2: Transmission & Prevention
Chairs: Laurel Lagenaur & Piotr Nowak
13:15hMicrobe: drug interactions and the impact on HIV infection and pathogenesis 
Nichole Klatt, University of Washington, USA
13:45hCervicovaginal microbial dynamics and its impact on HIV acquisition risk
Douglas Kwon, Ragon Institute of MGH, MIT and Harvard, USA
14:15Vaginal lactic acid inhibits production of pro-inflammatory mediators from human cervicovaginal epithelial cells associated with HIV acquisition (Abstract #: O_03)
Gilda Tachedjian, Australia
14:30Discussion & Session Evaluation
14:45Break & Poster Viewing (Abstract #: O_01 - O_04, P_01 - P_08) 
 
Session 3: GI Tract and Diet
Chairs: Nichole Klatt & Satya Dandekar
15:30h

Detrimental impact of a high fat diet on the natural history of SIV infection in non-human
Ivona Pandrea, University of Pittsburgh, USA

16:00h

Milk - guiding the infant microbiome 
Bruce German, University of California, Davis, USA

16:30hUnderstanding complexities of gut microbiome dysbiosis in HIV infected populations using a large cohort (Abstract #: O_04)
Abigail Armstrong, USA
16:45hPlasma tryptophan-kynurenine metabolites are altered with gut microbiota dysbiosis in HIV infection and associated with progression of carotid artery atherosclerosis (Abstract #: O_09)
Qibin Qi, USA
17:00hDiscussion & Session Evaluation
 
17:15Adjourn
 

Friday, October 20, 2017

Session 4: Comorbidities
Chairs: Alan Landay & Ronald Collman 
09:00hInflammatory bowel disease (IBD) and colon cancer and microbiome
William DePaolo, University of Washington, USA
09:30hMicrobial metabolites in HIV pathogenesis and comorbidities
Dana Gabuzda, Harvard Medical School, USA
10:00hComposite analysis of bacteriome and virome from HIV/HPV-coinfected pregnant women reveals proxies for intraepithelial lesions and immunodeficiency status (Abstract #: O_05)
Marcelo Soares, Brazil
10:15hDiscussion & Session Evaluation
10:30hBreak & Poster Viewing (Abstract #: O_05 - O_09, P_10 - P_16)
 
Session 5: Microbiome & Vaccines
Chairs: Que Dang & Angela Malaspina
11:30h

Aging, the microbiome and vaccine responses
Daria Hazuda, Merck, USA

12:00h

Mechanisms intersecting microbiota metabolomics with gut epithelial barrier repair in HIV infection
Satya Dandekar, University of California, Davis, USA

12:30hRole of the microbiome in HIV vaccine response heterogeneity
James Kublin, Fred Hutch and University of Washington, USA
13:00hEffect of high-risk sexual behaviour on diversity of the vaginal microbiota and abundance of lactobacillus (Abstract #: O_06)
Jocelyn Wessels, Canada
13:15h Discussion & Session Evaluation
 
13:30hLunch break
 
Session 6: Metabolomics Biologic and Technical issues
Chairs: Frederic Bushman & Roger Paredes
14:30hStudying the functional microbiome in vivo in HIV by metaproteomics approaches
Adam Burgener, University of Manitoba, Canada
15:00h

Fatty acid profiles differ in HIV infection, persist despite suppressive ART, and are associated with immune activation
Nicholas Funderburg, Ohio State University College of Medicine, USA

15:30hModulation of gut microbiota by indoleamine 2,3-dioxygenase 1 inhibitor during antiretroviral suppressed SIV infection in rhesus macaques (Abstract #: O_07)
Zhang Wang, USA
15:45hThe microbial-derived short chain fatty acid butyrate directly and differentially inhibits gut T helper cell subset activation and proliferation (Abstract #: O_08)
Jon Kibbie, USA
16:00hDiscussion & Session Evaluation
 
16:30hClosing remarks by workshop chair

 Posters

Paper ref. # TitlePresentation author
P_01Management of neurocognitive impairment in HIV patientsJason Brenchley, Italy
P_02Effects of advanced HIV disease on the dormant blood microbiotaSergio Serrano-Villar, Spain
P_03A role for dysbiotic bacteria in increased gastrointestinal neutrophil lifespan in treated HIV infectionTiffany Hensley-Mcbain, USA
P_04FuMi: A novel functional microbiome tool for metaproteomic datasets identified key bacterial pathways altered with pregnancy Sarah Mutch, Canada
P_05Depot-Medroxyprogesterone Acetate (DMPA) is associated with diversity of the vaginal microbiota and an altered vaginal microenvironment Jocelyn Wessels, Canada
P_06Cloud-based microbiome, metagenomic, and pathogen analysisHsinyi Tsang, USA
P_07Isolation of translocating bacteria in progressive SIV infection of rhesus macaques Jacob Flynn, USA
P_08Innovative pilot program on the diagnosis and management modulation of the diseases caused in the oral microbiomeKishore Shetty, USA
   
P_10Epidemiology of HIV/AIDS and syphilis among high risk groups in Pakistan Usman Waheed, Pakistan
P_11Promoting and creating awareness of HIV/AIDS in the black african communities in luton, United KingdomNelson Anti, UK
P_12Mobile HIV counselling and testing outreach: a model for community based approach to increasing uptake of HCT and antiretroviral therapy services in Benue State NigeriaGreg Abiaziem, Nigeria
P_13HIV-associated microbiome differences, geography, and inflammationDavid B Gootenberg, USA
P_14Microbiome Profiles of Chronic HIV-1 Infection under HAARTJemal Ali Mahdi, Ethiopia
P_15Molecular Epidemiology of HIV/AIDS in PakistanUsman Waheed, Pakistan
P_16Fecal microbiota composition drives immune activation in HIV-infected individualsCatherine Lozupone, USA

 

Program

The program of the Latin American Meeting on Viral Hepatitis and HIV Co-infection is currently being developed. A preliminary program can be downloaded here: PROGRAM

Invited speakers

 

Program

An exciting new program is being set up.
A Newsletter will be sent out as soon as registration opens and the new program is available.

The program of January 2014 is available by clicking on Final Program 4th HIV & Women

 

Program

We are proud to announce that the program has been set. For a full overview of the program, please click on the online program (righthand side of the website) or refer to the Program.

Please click here for more information on the Satellite Symposia.

Program

The Organizing Committee has developed a great program:
Click on the right for ONLINE PROGRAM and time schedule.
A program in pdf format can be downloaded here: Program 9th HIV Transmission ws 2014

All invited speakers:

 

 

 

 

 

Program

Click on the Online Program button (or your right hand side) to view the final version of the program.

The following invited speakers have confirmation their contribution:

Program

The Organizing Committee is currently finalizing the program. More information will be posted in due course. For a program outline, please visit the website of the 14th European Meeting on HIV & Hepatitis.

 

Program

 The Organizing Committee proudly presents the final workshop program: Final program 17HIVHEPPK

The following invited speakers have confirmed their contribution: